EP3687540A1 - Heteroaryl compounds as cxcr4 inhibitors, composition and method using the same - Google Patents
Heteroaryl compounds as cxcr4 inhibitors, composition and method using the sameInfo
- Publication number
- EP3687540A1 EP3687540A1 EP18859565.6A EP18859565A EP3687540A1 EP 3687540 A1 EP3687540 A1 EP 3687540A1 EP 18859565 A EP18859565 A EP 18859565A EP 3687540 A1 EP3687540 A1 EP 3687540A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- group
- cycloalkyl
- independently selected
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001072 heteroaryl group Chemical group 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims description 98
- 238000000034 method Methods 0.000 title abstract description 163
- 239000003112 inhibitor Substances 0.000 title description 8
- 101100441540 Xenopus laevis cxcr4-a gene Proteins 0.000 title 1
- 101100441541 Xenopus laevis cxcr4-b gene Proteins 0.000 title 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 230000037361 pathway Effects 0.000 claims abstract description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims description 488
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 230
- 150000001875 compounds Chemical class 0.000 claims description 152
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 150
- 229910052805 deuterium Inorganic materials 0.000 claims description 150
- -1 -OH Chemical group 0.000 claims description 102
- 229910052739 hydrogen Inorganic materials 0.000 claims description 92
- 125000003545 alkoxy group Chemical group 0.000 claims description 90
- 229910052757 nitrogen Inorganic materials 0.000 claims description 89
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 87
- 150000004820 halides Chemical class 0.000 claims description 83
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 68
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 67
- 125000004429 atom Chemical group 0.000 claims description 67
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 63
- 125000000623 heterocyclic group Chemical group 0.000 claims description 60
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 31
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 31
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 27
- 229910052717 sulfur Inorganic materials 0.000 claims description 27
- 229910052799 carbon Inorganic materials 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 24
- 239000012453 solvate Substances 0.000 claims description 20
- 125000005842 heteroatom Chemical group 0.000 claims description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 2
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 208000037357 HIV infectious disease Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000001344 Macular Edema Diseases 0.000 claims description 2
- 206010025415 Macular oedema Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
- 208000009277 Neuroectodermal Tumors Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 230000003042 antagnostic effect Effects 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229910052786 argon Inorganic materials 0.000 claims description 2
- 229910052797 bismuth Inorganic materials 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 239000003576 central nervous system agent Substances 0.000 claims description 2
- 229940125693 central nervous system agent Drugs 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000024207 chronic leukemia Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000011190 diabetic macular edema Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 230000011132 hemopoiesis Effects 0.000 claims description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 201000010230 macular retinal edema Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000001483 mobilizing effect Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims description 2
- 208000007538 neurilemmoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 2
- 206010039667 schwannoma Diseases 0.000 claims description 2
- 230000002269 spontaneous effect Effects 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 42
- 238000002360 preparation method Methods 0.000 abstract description 43
- 238000011282 treatment Methods 0.000 abstract description 14
- 230000008569 process Effects 0.000 abstract description 10
- 208000037765 diseases and disorders Diseases 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 429
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 218
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 180
- 239000000243 solution Substances 0.000 description 149
- 238000005481 NMR spectroscopy Methods 0.000 description 120
- 239000000047 product Substances 0.000 description 119
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 110
- 239000012044 organic layer Substances 0.000 description 92
- 238000010898 silica gel chromatography Methods 0.000 description 87
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 86
- 239000011541 reaction mixture Substances 0.000 description 84
- 238000006243 chemical reaction Methods 0.000 description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 64
- 239000007864 aqueous solution Substances 0.000 description 64
- 239000011734 sodium Substances 0.000 description 63
- 239000003921 oil Substances 0.000 description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 55
- 229920006395 saturated elastomer Polymers 0.000 description 52
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 239000007787 solid Substances 0.000 description 38
- 239000003208 petroleum Substances 0.000 description 34
- 238000010992 reflux Methods 0.000 description 33
- 239000000725 suspension Substances 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 28
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 27
- 235000011114 ammonium hydroxide Nutrition 0.000 description 27
- 239000000908 ammonium hydroxide Substances 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- 239000012230 colorless oil Substances 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 19
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 18
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 18
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 17
- 238000006467 substitution reaction Methods 0.000 description 17
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 150000001412 amines Chemical class 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 239000007858 starting material Substances 0.000 description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 13
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 238000007363 ring formation reaction Methods 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 229910052736 halogen Inorganic materials 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 229910052740 iodine Inorganic materials 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000009833 condensation Methods 0.000 description 8
- 230000005494 condensation Effects 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- ZXTRMHOUGKPHHM-UHFFFAOYSA-N n-methyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CN=C2C(NC)CCCC2=C1 ZXTRMHOUGKPHHM-UHFFFAOYSA-N 0.000 description 5
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 4
- UICZKLGFGMANCR-UHFFFAOYSA-N 4-chloro-6-(chloromethyl)pyrimidine Chemical compound ClCC1=CC(Cl)=NC=N1 UICZKLGFGMANCR-UHFFFAOYSA-N 0.000 description 4
- JIAKIQWNYAZUJD-UHFFFAOYSA-N 6,7-dihydro-5h-quinolin-8-one Chemical compound C1=CN=C2C(=O)CCCC2=C1 JIAKIQWNYAZUJD-UHFFFAOYSA-N 0.000 description 4
- MGCZHSNVSQPWNY-UHFFFAOYSA-N CC1=NC(=CC(=N1)CN(CCCC(=O)O)C=1C=CC=C2C=CC=NC=12)N1CCN(CC1)C Chemical compound CC1=NC(=CC(=N1)CN(CCCC(=O)O)C=1C=CC=C2C=CC=NC=12)N1CCN(CC1)C MGCZHSNVSQPWNY-UHFFFAOYSA-N 0.000 description 4
- VNBDJKQZECBNMB-UHFFFAOYSA-N CN(C1CCCC=2C=CC=NC1=2)CC1=NC=NC(=C1)N1CCNCC1 Chemical compound CN(C1CCCC=2C=CC=NC1=2)CC1=NC=NC(=C1)N1CCNCC1 VNBDJKQZECBNMB-UHFFFAOYSA-N 0.000 description 4
- MNALCHUSVLVHTJ-UHFFFAOYSA-N CN(C1CCCC=2C=CC=NC1=2)CC1=NC=NC=C1 Chemical compound CN(C1CCCC=2C=CC=NC1=2)CC1=NC=NC=C1 MNALCHUSVLVHTJ-UHFFFAOYSA-N 0.000 description 4
- OFXFMPOYFFCAOB-UHFFFAOYSA-N CNCC1=NC(=NC(=C1)N1CCN(CC1)C)C Chemical compound CNCC1=NC(=NC(=C1)N1CCN(CC1)C)C OFXFMPOYFFCAOB-UHFFFAOYSA-N 0.000 description 4
- VNBJBVGRUYTTMI-UHFFFAOYSA-N COC(C1=NC(=NC(=C1)N1CCN(CC1)C)SC)OC Chemical compound COC(C1=NC(=NC(=C1)N1CCN(CC1)C)SC)OC VNBJBVGRUYTTMI-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- QRVYMNXWKSQLLW-UHFFFAOYSA-N ClC1=CC(=NC=N1)CN(C1CCCC=2C=CC=NC1=2)C Chemical compound ClC1=CC(=NC=N1)CN(C1CCCC=2C=CC=NC1=2)C QRVYMNXWKSQLLW-UHFFFAOYSA-N 0.000 description 4
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000005660 chlorination reaction Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- RAEIRFVKAXHLHO-UHFFFAOYSA-N 4-chloro-6-(chloromethyl)-2-methylpyrimidine Chemical compound CC1=NC(Cl)=CC(CCl)=N1 RAEIRFVKAXHLHO-UHFFFAOYSA-N 0.000 description 3
- SIQGQNPJTGEYAA-UHFFFAOYSA-N 4-oxo-4-pyridin-2-ylbutanal Chemical compound O=CCCC(=O)C1=CC=CC=N1 SIQGQNPJTGEYAA-UHFFFAOYSA-N 0.000 description 3
- BMLCQHXPAJVVJH-UHFFFAOYSA-N 6-(chloromethyl)-2-methyl-1h-pyrimidin-4-one Chemical compound CC1=NC(=O)C=C(CCl)N1 BMLCQHXPAJVVJH-UHFFFAOYSA-N 0.000 description 3
- ZAKYERLVLCYWJN-UHFFFAOYSA-N 6-methylquinolin-8-amine Chemical compound N1=CC=CC2=CC(C)=CC(N)=C21 ZAKYERLVLCYWJN-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- AISQVXALLKVKPM-UHFFFAOYSA-N CN(C1CCCC=2C=CC=NC1=2)CC1=NC(=CC=C1)N1CCN(CC1)C Chemical compound CN(C1CCCC=2C=CC=NC1=2)CC1=NC(=CC=C1)N1CCN(CC1)C AISQVXALLKVKPM-UHFFFAOYSA-N 0.000 description 3
- BLXXOLFCZSFQJY-UHFFFAOYSA-N CN(C1CCCC=2C=CC=NC1=2)CC1=NC=CC(=N1)N1CCN(CC1)C Chemical compound CN(C1CCCC=2C=CC=NC1=2)CC1=NC=CC(=N1)N1CCN(CC1)C BLXXOLFCZSFQJY-UHFFFAOYSA-N 0.000 description 3
- BSFMOLJXYFLPCU-UHFFFAOYSA-N CN(C=1C=C(C=C2C=CC=NC=12)CO)CC1=NC(=NC(=C1)N1CCN(CC1)C)C Chemical compound CN(C=1C=C(C=C2C=CC=NC=12)CO)CC1=NC(=NC(=C1)N1CCN(CC1)C)C BSFMOLJXYFLPCU-UHFFFAOYSA-N 0.000 description 3
- UIDMJLDQPVBOLF-UHFFFAOYSA-N COC(C1=NC(=NC(=C1)N1CCN(CC1)C)S(=O)(=O)C)OC Chemical compound COC(C1=NC(=NC(=C1)N1CCN(CC1)C)S(=O)(=O)C)OC UIDMJLDQPVBOLF-UHFFFAOYSA-N 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 3
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 229910019213 POCl3 Inorganic materials 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000005576 amination reaction Methods 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- OKULHRWWYCFJAB-UHFFFAOYSA-N pyrimidine-4-carbaldehyde Chemical group O=CC1=CC=NC=N1 OKULHRWWYCFJAB-UHFFFAOYSA-N 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- LJRGBERXYNQPJI-UHFFFAOYSA-M sodium;3-nitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC=CC(S([O-])(=O)=O)=C1 LJRGBERXYNQPJI-UHFFFAOYSA-M 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- IEOYWWTZNZWUHL-UHFFFAOYSA-N (4,6-dichloro-2-methylpyrimidin-5-yl)methanol Chemical compound CC1=NC(Cl)=C(CO)C(Cl)=N1 IEOYWWTZNZWUHL-UHFFFAOYSA-N 0.000 description 2
- CMSLVSBXXUQEOG-UHFFFAOYSA-N 1,1-diphenyl-n-(pyridin-2-ylmethyl)methanimine Chemical compound C=1C=CC=NC=1CN=C(C=1C=CC=CC=1)C1=CC=CC=C1 CMSLVSBXXUQEOG-UHFFFAOYSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- VSOSXKMEQPYESP-UHFFFAOYSA-N 1,6-naphthyridine Chemical compound C1=CN=CC2=CC=CN=C21 VSOSXKMEQPYESP-UHFFFAOYSA-N 0.000 description 2
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical group COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 2
- AYLMBHYYHDDFAT-UHFFFAOYSA-N 1-oxido-1,5-naphthyridin-1-ium Chemical compound C1=CC=C2[N+]([O-])=CC=CC2=N1 AYLMBHYYHDDFAT-UHFFFAOYSA-N 0.000 description 2
- WDDUXTZCSPUUHD-UHFFFAOYSA-N 2-(3-methylpyrrolidin-2-yl)pyridine Chemical compound CC1CCNC1C1=CC=CC=N1 WDDUXTZCSPUUHD-UHFFFAOYSA-N 0.000 description 2
- HCJMUULXNLWIJC-UHFFFAOYSA-N 2-(bromomethyl)-4-chloropyrimidine Chemical compound ClC1=CC=NC(CBr)=N1 HCJMUULXNLWIJC-UHFFFAOYSA-N 0.000 description 2
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 2
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 2
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 2
- IBFBZKHFMPKUSV-UHFFFAOYSA-N 2-methyl-6-(4-methylpiperazin-1-yl)pyrimidine-4-carbaldehyde Chemical compound C1CN(C)CCN1C1=CC(C=O)=NC(C)=N1 IBFBZKHFMPKUSV-UHFFFAOYSA-N 0.000 description 2
- ZDFOPLZUQIKAKI-UHFFFAOYSA-N 2-methyl-6-(methylaminomethyl)-1h-pyrimidin-4-one Chemical compound CNCC1=CC(=O)N=C(C)N1 ZDFOPLZUQIKAKI-UHFFFAOYSA-N 0.000 description 2
- DQSQBZXDMHDHEO-UHFFFAOYSA-N 2-pyridin-2-ylpropan-2-amine Chemical compound CC(C)(N)C1=CC=CC=N1 DQSQBZXDMHDHEO-UHFFFAOYSA-N 0.000 description 2
- IPERFSCWSGDJII-UHFFFAOYSA-N 3-[(4-methoxyphenyl)methylamino]pyridine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1CNC1=CC=CN=C1C#N IPERFSCWSGDJII-UHFFFAOYSA-N 0.000 description 2
- LKVDHLFOBICUJO-UHFFFAOYSA-N 4-(dimethoxymethyl)-2-methyl-1H-pyrimidin-6-one Chemical compound COC(OC)c1cc(=O)nc(C)[nH]1 LKVDHLFOBICUJO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- UCTNTYHJFWMUBD-UHFFFAOYSA-N 4-chloro-3-oxobutanoic acid Chemical class OC(=O)CC(=O)CCl UCTNTYHJFWMUBD-UHFFFAOYSA-N 0.000 description 2
- BPSGVKFIQZZFNH-UHFFFAOYSA-N 4-hydroxy-2-methyl-1h-pyrimidin-6-one Chemical compound CC1=NC(O)=CC(=O)N1 BPSGVKFIQZZFNH-UHFFFAOYSA-N 0.000 description 2
- DFYPWUZXTWLPSC-UHFFFAOYSA-N 5,6,8-trifluoroquinoline Chemical compound N1=CC=CC2=C(F)C(F)=CC(F)=C21 DFYPWUZXTWLPSC-UHFFFAOYSA-N 0.000 description 2
- XKUDKZLYJZKDOH-UHFFFAOYSA-N 5-fluoro-6-(fluoromethyl)-2-methyl-1h-pyrimidin-4-one Chemical compound CC1=NC(=O)C(F)=C(CF)N1 XKUDKZLYJZKDOH-UHFFFAOYSA-N 0.000 description 2
- XJZYFWNWTOAHTR-UHFFFAOYSA-N 6-(chloromethyl)-2-methylsulfanyl-1h-pyrimidin-4-one Chemical compound CSC1=NC(=O)C=C(CCl)N1 XJZYFWNWTOAHTR-UHFFFAOYSA-N 0.000 description 2
- VPRQZLQIQHFCHO-UHFFFAOYSA-N 6-(dimethoxymethyl)-2-methylsulfanyl-1h-pyrimidin-4-one Chemical compound COC(OC)C1=CC(=O)N=C(SC)N1 VPRQZLQIQHFCHO-UHFFFAOYSA-N 0.000 description 2
- APXIIWAJZKHFIV-UHFFFAOYSA-N 6-methyl-8-nitroquinoline Chemical compound N1=CC=CC2=CC(C)=CC([N+]([O-])=O)=C21 APXIIWAJZKHFIV-UHFFFAOYSA-N 0.000 description 2
- HGGWYJGOBNJZRY-UHFFFAOYSA-N 8-chloro-5,6,7,8-tetrahydroquinoline Chemical compound C1=CN=C2C(Cl)CCCC2=C1 HGGWYJGOBNJZRY-UHFFFAOYSA-N 0.000 description 2
- WOSYAMNMWPZLGF-UHFFFAOYSA-N 8-fluoro-5-nitroquinoline Chemical compound C1=CC=C2C([N+](=O)[O-])=CC=C(F)C2=N1 WOSYAMNMWPZLGF-UHFFFAOYSA-N 0.000 description 2
- RNAAXKYOTPSFGV-UHFFFAOYSA-N 8-fluoroquinoline Chemical compound C1=CN=C2C(F)=CC=CC2=C1 RNAAXKYOTPSFGV-UHFFFAOYSA-N 0.000 description 2
- OQHHSGRZCKGLCY-UHFFFAOYSA-N 8-nitroquinoline Chemical class C1=CN=C2C([N+](=O)[O-])=CC=CC2=C1 OQHHSGRZCKGLCY-UHFFFAOYSA-N 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- BCCVWAIDVGMKOL-UHFFFAOYSA-N BrC1=CC=CC(=N1)CN(C1CCCC=2C=CC=NC1=2)C Chemical compound BrC1=CC=CC(=N1)CN(C1CCCC=2C=CC=NC1=2)C BCCVWAIDVGMKOL-UHFFFAOYSA-N 0.000 description 2
- PGZGGJCKUWJTRB-UHFFFAOYSA-N C(C)(=O)C1=NC=CC=C1NS(=O)(=O)C Chemical compound C(C)(=O)C1=NC=CC=C1NS(=O)(=O)C PGZGGJCKUWJTRB-UHFFFAOYSA-N 0.000 description 2
- CLVFDDBBKGVZQS-UHFFFAOYSA-N C1(=CC=CC=C1)C(C1=CC=CC=C1)=NC(C(CC(=O)OCC)C)C1=NC=CC=C1 Chemical compound C1(=CC=CC=C1)C(C1=CC=CC=C1)=NC(C(CC(=O)OCC)C)C1=NC=CC=C1 CLVFDDBBKGVZQS-UHFFFAOYSA-N 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- JDUYPZHHRSKZRW-UHFFFAOYSA-N CC(C)(NC=O)C1=NC=CC=C1 Chemical compound CC(C)(NC=O)C1=NC=CC=C1 JDUYPZHHRSKZRW-UHFFFAOYSA-N 0.000 description 2
- IXTJWGUECRRXMO-UHFFFAOYSA-N CC1CC(NC1C1=NC=CC=C1)=O Chemical compound CC1CC(NC1C1=NC=CC=C1)=O IXTJWGUECRRXMO-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- DXLFUYUKLXQHIF-UHFFFAOYSA-N CN(C1=CC=C(C=2C=CC=NC1=2)N)CC1=NC(=NC(=C1)N1CCN(CC1)C)C Chemical compound CN(C1=CC=C(C=2C=CC=NC1=2)N)CC1=NC(=NC(=C1)N1CCN(CC1)C)C DXLFUYUKLXQHIF-UHFFFAOYSA-N 0.000 description 2
- JBWLFTYJPUPJPI-UHFFFAOYSA-N CN(C1=NC(=CC(=N1)C=O)N1CCN(CC1)C)C Chemical compound CN(C1=NC(=CC(=N1)C=O)N1CCN(CC1)C)C JBWLFTYJPUPJPI-UHFFFAOYSA-N 0.000 description 2
- IVBTTWLHAFYMEJ-UHFFFAOYSA-N CN(C=1C=CC(=C2C=CC=NC=12)[N+](=O)[O-])CC1=NC(=NC(=C1)N1CCN(CC1)C)C Chemical compound CN(C=1C=CC(=C2C=CC=NC=12)[N+](=O)[O-])CC1=NC(=NC(=C1)N1CCN(CC1)C)C IVBTTWLHAFYMEJ-UHFFFAOYSA-N 0.000 description 2
- MESZVPVMBHHHGR-UHFFFAOYSA-N COC(C1=NC(=NC(=C1)N1CCN(CC1)C)C)OC Chemical compound COC(C1=NC(=NC(=C1)N1CCN(CC1)C)C)OC MESZVPVMBHHHGR-UHFFFAOYSA-N 0.000 description 2
- XAMRMNVAGAVQLX-UHFFFAOYSA-N COC(C1=NC(=NC(=C1)N1CCN(CC1)C)C1=CC=CC=C1)OC Chemical compound COC(C1=NC(=NC(=C1)N1CCN(CC1)C)C1=CC=CC=C1)OC XAMRMNVAGAVQLX-UHFFFAOYSA-N 0.000 description 2
- KNRYKTICGWKSDY-UHFFFAOYSA-N COC(C1=NC(=NC(=C1)N1CCN(CC1)C)N(C)C)OC Chemical compound COC(C1=NC(=NC(=C1)N1CCN(CC1)C)N(C)C)OC KNRYKTICGWKSDY-UHFFFAOYSA-N 0.000 description 2
- XJXKAMNKHAZLAJ-UHFFFAOYSA-N COC(C1=NC(=NC(=C1)N1CCN(CC1)C)OCC)OC Chemical compound COC(C1=NC(=NC(=C1)N1CCN(CC1)C)OCC)OC XJXKAMNKHAZLAJ-UHFFFAOYSA-N 0.000 description 2
- MYDQFRKZTYIBAY-UHFFFAOYSA-N ClC1=NC(=NC=C1)CN(C1CCCC=2C=CC=NC1=2)C Chemical compound ClC1=NC(=NC=C1)CN(C1CCCC=2C=CC=NC1=2)C MYDQFRKZTYIBAY-UHFFFAOYSA-N 0.000 description 2
- WRRQHFFNAKKEHV-UHFFFAOYSA-N FC1(CCC=2C=CC=NC=2C1=O)F Chemical compound FC1(CCC=2C=CC=NC=2C1=O)F WRRQHFFNAKKEHV-UHFFFAOYSA-N 0.000 description 2
- NEKWTUCZIPFLLC-UHFFFAOYSA-N FC=1C(=NC(=NC=1N1CCN(CC1)C)C)CF Chemical compound FC=1C(=NC(=NC=1N1CCN(CC1)C)C)CF NEKWTUCZIPFLLC-UHFFFAOYSA-N 0.000 description 2
- 238000003747 Grignard reaction Methods 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- 238000006845 Michael addition reaction Methods 0.000 description 2
- UBDWGRQCOSBCIW-UHFFFAOYSA-N N-(2-acetylpyridin-3-yl)acetamide Chemical compound CC(=O)Nc1cccnc1C(C)=O UBDWGRQCOSBCIW-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 229910020667 PBr3 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 2
- OHLRLMWUFVDREV-UHFFFAOYSA-N ethyl 4-chloro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CCl OHLRLMWUFVDREV-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 238000003328 mesylation reaction Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- PJYQRBMGZRVNSQ-UHFFFAOYSA-N methyl 4,4-dimethoxy-3-oxobutanoate Chemical compound COC(OC)C(=O)CC(=O)OC PJYQRBMGZRVNSQ-UHFFFAOYSA-N 0.000 description 2
- OSELUCGIXBWQKO-UHFFFAOYSA-N n-methyl-1-(3-methylpyridin-2-yl)ethanamine Chemical compound CNC(C)C1=NC=CC=C1C OSELUCGIXBWQKO-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 2
- PXIGSUWVCSOFMF-UHFFFAOYSA-N spiro[2.5]octan-6-one Chemical compound C1CC(=O)CCC11CC1 PXIGSUWVCSOFMF-UHFFFAOYSA-N 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- ROVPREHMYVPCBD-UHFFFAOYSA-N tert-butyl 4-[6-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]pyrimidin-4-yl]piperazine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCN(CC1)C1=NC=NC(=C1)CN(C1CCCC=2C=CC=NC1=2)C ROVPREHMYVPCBD-UHFFFAOYSA-N 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
- GBYJDWHKTMNWIP-QWHCGFSZSA-N (1S)-1-(4-methoxyphenyl)-N-[(1R)-1-pyridin-2-ylethyl]ethanamine Chemical compound COC1=CC=C(C=C1)[C@H](C)N[C@H](C)C1=NC=CC=C1 GBYJDWHKTMNWIP-QWHCGFSZSA-N 0.000 description 1
- GBYJDWHKTMNWIP-STQMWFEESA-N (1S)-1-(4-methoxyphenyl)-N-[(1S)-1-pyridin-2-ylethyl]ethanamine Chemical compound COC1=CC=C(C=C1)[C@H](C)N[C@@H](C)C1=NC=CC=C1 GBYJDWHKTMNWIP-STQMWFEESA-N 0.000 description 1
- JTDGKQNNPKXKII-SSDOTTSWSA-N (1r)-1-(4-methoxyphenyl)ethanamine Chemical compound COC1=CC=C([C@@H](C)N)C=C1 JTDGKQNNPKXKII-SSDOTTSWSA-N 0.000 description 1
- JTDGKQNNPKXKII-ZETCQYMHSA-N (1s)-1-(4-methoxyphenyl)ethanamine Chemical compound COC1=CC=C([C@H](C)N)C=C1 JTDGKQNNPKXKII-ZETCQYMHSA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- HOBMGFDJYBEWLS-UHFFFAOYSA-N (2-methylpyrimidin-5-yl)methanol Chemical compound CC1=NC=C(CO)C=N1 HOBMGFDJYBEWLS-UHFFFAOYSA-N 0.000 description 1
- BODRLAXXPQWIQM-UHFFFAOYSA-N (6-chloropyrimidin-4-yl)methanol Chemical compound OCC1=CC(Cl)=NC=N1 BODRLAXXPQWIQM-UHFFFAOYSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- JTDGKQNNPKXKII-UHFFFAOYSA-N 1-(4-methoxyphenyl)ethanamine Chemical compound COC1=CC=C(C(C)N)C=C1 JTDGKQNNPKXKII-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- QMYVWJVVVMIBMM-UHFFFAOYSA-N 2,4,5-trifluoroaniline Chemical compound NC1=CC(F)=C(F)C=C1F QMYVWJVVVMIBMM-UHFFFAOYSA-N 0.000 description 1
- DRUMUCBBNROIBG-UHFFFAOYSA-N 2,6-dimethyl-4-oxo-1h-pyrimidine-5-carbonitrile Chemical compound CC1=NC(=O)C(C#N)=C(C)N1 DRUMUCBBNROIBG-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- NDCZQFDBSPOUDF-SECBINFHSA-N 2-[(2r)-pyrrolidin-2-yl]pyridine Chemical compound C1CCN[C@H]1C1=CC=CC=N1 NDCZQFDBSPOUDF-SECBINFHSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XFKYKTBPRBZDFG-UHFFFAOYSA-N 2-aminoacetonitrile;hydrochloride Chemical compound Cl.NCC#N XFKYKTBPRBZDFG-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- FTZQXOJYPFINKJ-UHFFFAOYSA-N 2-fluoroaniline Chemical compound NC1=CC=CC=C1F FTZQXOJYPFINKJ-UHFFFAOYSA-N 0.000 description 1
- 102100027324 2-hydroxyacyl-CoA lyase 1 Human genes 0.000 description 1
- FNWVSOBTBPEVDU-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)pyrimidine Chemical compound C1CN(C)CCN1C1=CC=NC(C)=N1 FNWVSOBTBPEVDU-UHFFFAOYSA-N 0.000 description 1
- DLURHXYXQYMPLT-UHFFFAOYSA-N 2-nitro-p-toluidine Chemical compound CC1=CC=C(N)C([N+]([O-])=O)=C1 DLURHXYXQYMPLT-UHFFFAOYSA-N 0.000 description 1
- DPJCXCZTLWNFOH-UHFFFAOYSA-N 2-nitroaniline Chemical compound NC1=CC=CC=C1[N+]([O-])=O DPJCXCZTLWNFOH-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- NDCZQFDBSPOUDF-UHFFFAOYSA-N 2-pyrrolidin-2-ylpyridine Chemical compound C1CCNC1C1=CC=CC=N1 NDCZQFDBSPOUDF-UHFFFAOYSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- XIUQTIJGWYPOMB-UHFFFAOYSA-N 3-[4-[6-[[methyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]pyrimidin-4-yl]piperazin-1-yl]propanenitrile Chemical compound CN(C1CCCC=2C=CC=NC1=2)CC1=CC(=NC=N1)N1CCN(CC1)CCC#N XIUQTIJGWYPOMB-UHFFFAOYSA-N 0.000 description 1
- VZFPSCNTFBJZHB-UHFFFAOYSA-N 3-fluoropyridine-2-carbonitrile Chemical compound FC1=CC=CN=C1C#N VZFPSCNTFBJZHB-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000005925 3-methylpentyloxy group Chemical group 0.000 description 1
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
- MDHHILKUOBIENR-UHFFFAOYSA-N 4,4-dimethoxy-3-oxobutanoic acid Chemical compound COC(OC)C(=O)CC(O)=O MDHHILKUOBIENR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- JQVDISNYQMXLRW-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)pyrimidine Chemical group C1CN(C)CCN1C1=CC=NC=N1 JQVDISNYQMXLRW-UHFFFAOYSA-N 0.000 description 1
- BREBLOQLDAMOQJ-UHFFFAOYSA-N 4-(bromomethyl)-6-chloropyrimidine Chemical compound ClC1=CC(CBr)=NC=N1 BREBLOQLDAMOQJ-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- WDTVJRYCMIZPMX-UHFFFAOYSA-N 4-chloro-2-methylpyrimidine Chemical compound CC1=NC=CC(Cl)=N1 WDTVJRYCMIZPMX-UHFFFAOYSA-N 0.000 description 1
- FGHUCGUSRVUUSV-UHFFFAOYSA-N 4-chloro-6-(chloromethyl)-2-methylsulfanylpyrimidine Chemical compound CSC1=NC(Cl)=CC(CCl)=N1 FGHUCGUSRVUUSV-UHFFFAOYSA-N 0.000 description 1
- DBPKMSBWOKAKLA-UHFFFAOYSA-N 4-chloropyrimidine Chemical compound ClC1=CC=NC=N1 DBPKMSBWOKAKLA-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- YQDGQEKUTLYWJU-UHFFFAOYSA-N 5,6,7,8-tetrahydroquinoline Chemical compound C1=CC=C2CCCCC2=N1 YQDGQEKUTLYWJU-UHFFFAOYSA-N 0.000 description 1
- ANDWKDRELVPNDM-UHFFFAOYSA-N 6-bromo-3-methylpyridin-2-amine Chemical compound CC1=CC=C(Br)N=C1N ANDWKDRELVPNDM-UHFFFAOYSA-N 0.000 description 1
- BKLJUYPLUWUEOQ-UHFFFAOYSA-N 6-bromopyridin-2-amine Chemical compound NC1=CC=CC(Br)=N1 BKLJUYPLUWUEOQ-UHFFFAOYSA-N 0.000 description 1
- QWFHFNGMCPMOCD-UHFFFAOYSA-N 6-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=CC(C=O)=N1 QWFHFNGMCPMOCD-UHFFFAOYSA-N 0.000 description 1
- QSYXOSUECWOEOF-UHFFFAOYSA-N 7-fluoroquinolin-8-amine Chemical compound C1=CN=C2C(N)=C(F)C=CC2=C1 QSYXOSUECWOEOF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical group C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001251200 Agelas Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- AWNTWTPSTAFVLX-UHFFFAOYSA-N BrC1=C2C=CC=NC2=C(C=C1)N(CC1=NC(=NC(=C1)N1CCN(CC1)C)C)C Chemical compound BrC1=C2C=CC=NC2=C(C=C1)N(CC1=NC(=NC(=C1)N1CCN(CC1)C)C)C AWNTWTPSTAFVLX-UHFFFAOYSA-N 0.000 description 1
- GGZXPOVZZREZJK-UHFFFAOYSA-N BrC1=CC=C2C=CC=NC2=C1N(CC1=NC(=NC(=C1)N1CCN(CC1)C)C)C Chemical compound BrC1=CC=C2C=CC=NC2=C1N(CC1=NC(=NC(=C1)N1CCN(CC1)C)C)C GGZXPOVZZREZJK-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- IQAGPKBZPCCAAE-UHFFFAOYSA-N C(C)OC1=NC(=CC(=N1)C=O)N1CCN(CC1)C Chemical compound C(C)OC1=NC(=CC(=N1)C=O)N1CCN(CC1)C IQAGPKBZPCCAAE-UHFFFAOYSA-N 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- MWKKNNLVCGHGLP-UHFFFAOYSA-N CC1=NC(=CC(=N1)CN(CCCC(=O)N)C=1C=CC=C2C=CC=NC=12)N1CCN(CC1)C Chemical compound CC1=NC(=CC(=N1)CN(CCCC(=O)N)C=1C=CC=C2C=CC=NC=12)N1CCN(CC1)C MWKKNNLVCGHGLP-UHFFFAOYSA-N 0.000 description 1
- HYNVAJGOXZVGCX-UHFFFAOYSA-N CC1=NC(=CC(=N1)CNC=1C=CC=C2C=CC=NC=12)N1CCN(CC1)C Chemical compound CC1=NC(=CC(=N1)CNC=1C=CC=C2C=CC=NC=12)N1CCN(CC1)C HYNVAJGOXZVGCX-UHFFFAOYSA-N 0.000 description 1
- JBMFUTZFKCPWOQ-UHFFFAOYSA-N CN(C1CCCC=2C=CC=NC1=2)CC1=NC(=NC(=C1)N1CCN(CC1)C)C Chemical compound CN(C1CCCC=2C=CC=NC1=2)CC1=NC(=NC(=C1)N1CCN(CC1)C)C JBMFUTZFKCPWOQ-UHFFFAOYSA-N 0.000 description 1
- WBGPQNNJIGFTNX-UHFFFAOYSA-N CN(C=1C(=CC=C2C=CC=NC=12)C#N)CC1=NC(=NC(=C1)N1CCN(CC1)C)C Chemical compound CN(C=1C(=CC=C2C=CC=NC=12)C#N)CC1=NC(=NC(=C1)N1CCN(CC1)C)C WBGPQNNJIGFTNX-UHFFFAOYSA-N 0.000 description 1
- OPSQXMVGTCUQSQ-UHFFFAOYSA-N CN(C=1C=C(C=C2C=CC=NC=12)N)CC1=NC(=NC(=C1)N1CCN(CC1)C)C Chemical compound CN(C=1C=C(C=C2C=CC=NC=12)N)CC1=NC(=NC(=C1)N1CCN(CC1)C)C OPSQXMVGTCUQSQ-UHFFFAOYSA-N 0.000 description 1
- KFUGATOCXQCIDB-UHFFFAOYSA-N CN(C=1C=C(C=C2C=CC=NC=12)NS(=O)(=O)C)CC1=NC(=NC(=C1)N1CCN(CC1)C)C Chemical compound CN(C=1C=C(C=C2C=CC=NC=12)NS(=O)(=O)C)CC1=NC(=NC(=C1)N1CCN(CC1)C)C KFUGATOCXQCIDB-UHFFFAOYSA-N 0.000 description 1
- YSCKLGXHYHHXEO-UHFFFAOYSA-N CN(C=1C=CC(=C2C=CC=NC=12)NS(=O)(=O)C)CC1=NC(=NC(=C1)N1CCN(CC1)C)C Chemical compound CN(C=1C=CC(=C2C=CC=NC=12)NS(=O)(=O)C)CC1=NC(=NC(=C1)N1CCN(CC1)C)C YSCKLGXHYHHXEO-UHFFFAOYSA-N 0.000 description 1
- FNBGIYCIFXJOOT-UHFFFAOYSA-N CN(C=1C=CC(=C2C=CC=NC=12)S(=O)(=O)C)CC1=NC(=NC(=C1)N1CCN(CC1)C)C Chemical compound CN(C=1C=CC(=C2C=CC=NC=12)S(=O)(=O)C)CC1=NC(=NC(=C1)N1CCN(CC1)C)C FNBGIYCIFXJOOT-UHFFFAOYSA-N 0.000 description 1
- LBCVTARDQMLTQA-UHFFFAOYSA-N CN(C=1C=CC=C2C=CC=NC=12)CC1=NC(=NC(=C1)N1CCN(CC1)C)C Chemical compound CN(C=1C=CC=C2C=CC=NC=12)CC1=NC(=NC(=C1)N1CCN(CC1)C)C LBCVTARDQMLTQA-UHFFFAOYSA-N 0.000 description 1
- NBJYZFLVHJXMDY-UHFFFAOYSA-N CN(C=1C=CC=C2CCCNC=12)CC1=NC=NC(=C1)N1CCN(CC1)C Chemical compound CN(C=1C=CC=C2CCCNC=12)CC1=NC=NC(=C1)N1CCN(CC1)C NBJYZFLVHJXMDY-UHFFFAOYSA-N 0.000 description 1
- XMOABVSAODEPTO-UHFFFAOYSA-N CN1CCN(CC1)C1=CC(=NC(=N1)C1=CC=CC=C1)C=O Chemical compound CN1CCN(CC1)C1=CC(=NC(=N1)C1=CC=CC=C1)C=O XMOABVSAODEPTO-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- ZFDIRQKJPRINOQ-HWKANZROSA-N Ethyl crotonate Chemical compound CCOC(=O)\C=C\C ZFDIRQKJPRINOQ-HWKANZROSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- FXYKLVFTWJYJFE-UHFFFAOYSA-N FC1(CCC=2C=CC=NC=2C1NC)F Chemical compound FC1(CCC=2C=CC=NC=2C1NC)F FXYKLVFTWJYJFE-UHFFFAOYSA-N 0.000 description 1
- XGVAFDXCNMCDFF-UHFFFAOYSA-N FC1=C2C=CC=NC2=C(C=C1F)NC Chemical compound FC1=C2C=CC=NC2=C(C=C1F)NC XGVAFDXCNMCDFF-UHFFFAOYSA-N 0.000 description 1
- CIPOQASXSXXJIK-UHFFFAOYSA-N FC1=CC=C2C=CC=NC2=C1NCC1=CC=C(C=C1)OC Chemical compound FC1=CC=C2C=CC=NC2=C1NCC1=CC=C(C=C1)OC CIPOQASXSXXJIK-UHFFFAOYSA-N 0.000 description 1
- WMEHBBIQEDSPKV-UHFFFAOYSA-N FC=1CCC=2C=CC=NC=2C=1N(CC1=NC(=NC(=C1)N1CCN(CC1)C)C)C Chemical compound FC=1CCC=2C=CC=NC=2C=1N(CC1=NC(=NC(=C1)N1CCN(CC1)C)C)C WMEHBBIQEDSPKV-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 101001009252 Homo sapiens 2-hydroxyacyl-CoA lyase 1 Proteins 0.000 description 1
- 101000694017 Homo sapiens Sodium channel protein type 5 subunit alpha Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- OIMZZUFXLRMAPU-UHFFFAOYSA-N I.CNc1cc(C)cc2cccnc12 Chemical compound I.CNc1cc(C)cc2cccnc12 OIMZZUFXLRMAPU-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- ULMHMJAEGZPQRY-UHFFFAOYSA-N N-(tert-butoxycarbonyl)piperidin-2-one Chemical compound CC(C)(C)OC(=O)N1CCCCC1=O ULMHMJAEGZPQRY-UHFFFAOYSA-N 0.000 description 1
- LPTRCGOYHAYNCF-UHFFFAOYSA-N N-methyl-N-[[6-(4-methylpiperazin-1-yl)pyrimidin-4-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CN(Cc1cc(ncn1)N1CCN(C)CC1)C1CCCc2cccnc12 LPTRCGOYHAYNCF-UHFFFAOYSA-N 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- LOXYOUBAWLDXPF-JTQLQIEISA-N OC1=CC(=NC(=N1)SC)[C@H]1N(CCC1)C(=O)OC(C)(C)C Chemical compound OC1=CC(=NC(=N1)SC)[C@H]1N(CCC1)C(=O)OC(C)(C)C LOXYOUBAWLDXPF-JTQLQIEISA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000000297 Sandmeyer reaction Methods 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 1
- QWBAOXACRYJBED-UHFFFAOYSA-N [Cl].C1=CN=CN=C1 Chemical compound [Cl].C1=CN=CN=C1 QWBAOXACRYJBED-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- DFNYGALUNNFWKJ-UHFFFAOYSA-N aminoacetonitrile Chemical compound NCC#N DFNYGALUNNFWKJ-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- SFJMFSWCBVEHBA-UHFFFAOYSA-M copper(i)-thiophene-2-carboxylate Chemical compound [Cu+].[O-]C(=O)C1=CC=CS1 SFJMFSWCBVEHBA-UHFFFAOYSA-M 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 1
- 125000004966 cyanoalkyl group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- DBIGLYQTWDJYJI-UHFFFAOYSA-N ethyl 2,4-difluoro-3-oxobutanoate Chemical compound CCOC(=O)C(F)C(=O)CF DBIGLYQTWDJYJI-UHFFFAOYSA-N 0.000 description 1
- VCYZVXRKYPKDQB-UHFFFAOYSA-N ethyl 2-fluoroacetate Chemical compound CCOC(=O)CF VCYZVXRKYPKDQB-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001647 gastrula Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- RWHJVIIQVLECOW-UHFFFAOYSA-N lithium;pyridine Chemical compound [Li].C1=CC=NC=C1 RWHJVIIQVLECOW-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- OKSFXFYCVCFNCH-UHFFFAOYSA-N methyl 8-[methyl-[[2-methyl-6-(4-methylpiperazin-1-yl)pyrimidin-4-yl]methyl]amino]quinoline-6-carboxylate Chemical compound N1(CCN(CC1)C)C1=NC(=NC(=C1)CN(C1=C2N=CC=CC2=CC(C(=O)OC)=C1)C)C OKSFXFYCVCFNCH-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NKBKRVWPGIIUGY-UHFFFAOYSA-N n-ethyl-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1=CN=C2C(NCC)CCCC2=C1 NKBKRVWPGIIUGY-UHFFFAOYSA-N 0.000 description 1
- BNBIFCUPKFVQJA-UHFFFAOYSA-N n-methyl-2-pyridin-2-ylpropan-2-amine Chemical compound CNC(C)(C)C1=CC=CC=N1 BNBIFCUPKFVQJA-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 1
- 229960002169 plerixafor Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical group NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 101150074703 sun gene Proteins 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000006337 tetrafluoro ethyl group Chemical group 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 125000004149 thio group Chemical class *S* 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
- C07F7/0836—Compounds with one or more Si-OH or Si-O-metal linkage
Definitions
- the present invention generally relates to heteroaryl compounds and, more particularly, relates to novel heteroaryl compounds that are useful in the therapies targeting C-X-C chemokine receptor type 4 (CXCR4) inhibitors, and use of the CXCR4 inhibitors for therapeutic intervention in infectious diseases, inflammatory diseases, tumors, and cancers.
- CXCR4 C-X-C chemokine receptor type 4
- C-X-C chemokine receptor type 4 (CXCR4) is a transmembrane protein that belongs to the G-protein-coupled receptors and it is involved in physiological processes in the hematopoietic and immune systems. Studies show that CXCR4 is expressed in tissues including lymphatic tissues, thymus, brain, spleen, stomach and small intestine. CXCR4 /transmits signals from its natural chemokine ligand, stromal cell-derived factor (SDF)-la, to intracellular biological pathways via G-proteins.
- SDF stromal cell-derived factor
- CXCR4 and SDF-la have been targeted in various therapeutic treatments for a number of diseases, including, for example, human immunodeficiency virus (HIV) infection, cancers, tumors, and inflammation and autoimmune disease such as rheumatoid arthritis and allergic asthma.
- HIV human immunodeficiency virus
- Plerixafor was approved by the FDA in 2008 for the mobilization of hematopoietic stem cells. See Cho W.T.. et al., /. Med. Chem. 2011; 55: 977-94; Debnath B. et al., Theranostics 2013, 3 (1): 47-75.
- heteroaryl compounds as CXCR4 inhibitors, and compositions and applications thereof. These disclosed heteroaryl compounds, and compositions and applications thereof, may effectively inhibit necrosis, thereby finding application in treatments of necrotic pathway-related diseases and disorders, including, for example, inflammation, tumors, metabolic diseases and neurodegenerative diseases such as cerebral ischemia and stroke.
- Ar is 5-10 membered heteroaryl comprising one N and 1-3 additional heteroatoms independently selected from the group consisting of N, O, and S, and Ar is unsubstituted or substituted with 1-4 I1 ⁇ 2;
- W is , each X is independently a bond, CR 3 2R 33 , O, NR 3 4,
- Y is , wherein the carbon bonded with R 3 is bonded with the carbon bonded with R2;
- D 3 is N or CR' 4
- Di is NR' 4 , O, S or C(R' 4 ) 2 ,
- D 3 is N or CR' 4
- O t is NR' 4
- D 2 is
- R 7 is selected from the group consisting of H, deuterium, Ci_6 alkyl, C 3 -6 cycloalkyl, and C 3 -6 heterocycloalkyl, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, and C 3 -6
- each of Rg and R9 is independently selected from the group consisting of H, deuterium, -CN, Ci-6 alkyl, and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, and C 1 -3 alkoxy; or R 7 and Rg, and atoms attached thereto, form a ring;
- R 3 1 is selected from the group consisting of deuterium, halide, -CN, -OH, amino, Ci_6 alkyl, C 3 -6 cycloalkyl, Ci -8 alkoxy, C2-6 alkynyl, C2-6 alkenyl, -S(Ci_6 alkyl), -NH(Ci_6 alkyl), -N(Ci_6 alkyl) 2 , aryl, 5-7 membered heteroaryl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, and 5-7 membered heterocycle comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, Ci_6 alkoxy, aryl, heteroaryl, and heterocycle is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of deuterium, halide, -CN, -OH, amino, Ci_
- the disclosed compound is according Formula la
- Ar is unsubstituted or substituted with 1-4 groups of R 3 1, and Ar is selected from the group consisting of:
- each X is independently a bond, CR 3 2R 33 , O, or NR 3 4;
- each of R19, R20, R21, R22, R25, R26, R27, R28, R29, and R30 is independently selected from the group consisting of H, deuterium, -CN, -OH, Ci_6 alkyl, C 3 -6 cycloalkyl, and C1-3 alkoxy, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, and C1-3 alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, Ci_6 alkyl, and C1-3 alkoxy; or R19 and R27, together with atoms they attached to, form a ring; or R21 and R27, together with atoms they attached to, form a ring;
- each of R2 3 and R24 is independently selected from the group consisting of H, Ci_6 alkyl, and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, Ci_6 alkyl, and C1-3 alkoxy; or R22 and R2 3 , together with atoms they attached to, form a 5-7 membered heterocycle;
- R 3 1 is selected from the group consisting of deuterium, halide, -CN, -OH, amino, Ci_6 alkyl, C 3 -6 cycloalkyl, Ci_6 alkoxy, C2-6 alkynyl, C2-6 alkenyl, -S(Ci_6 alkyl), -NH(Ci_6 alkyl), -N(Ci_6 alkyl)2, aryl, 5-7 membered heteroaryl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, and 5-7 membered heterocycle comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, Ci_6 alkoxy, aryl, heteroaryl, and heterocycle is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of deuterium, halide, -CN, -OH, amino, Ci_6 al
- the disclosed compound is according to Formula lb:
- Ar is unsubstituted or substituted with 1-4 groups of R31 , and Ar is selected from the group consisting of:
- each X is independently a bond, CR 3 2R 33 , O, or NR 3 4;
- each of R19, R20, R21, R22, R25, R26, R27, R28, R29, and R30 is independently selected from the group consisting of H, deuterium, -CN, -OH, Ci_6 alkyl, C 3 -6 cycloalkyl, and C1-3 alkoxy, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, and C1-3 alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, Ci_6 alkyl, and C1-3 alkoxy; or R19 and R27, together with atoms they attached to, form a ring; or R21 and R27, together with atoms they attached to, form a ring;
- each of R2 3 and R24 is independently selected from the group consisting of H, Ci_6 alkyl, and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, Ci_6 alkyl, and C1-3 alkoxy; or R22 and R2 3 , together with atoms they attached to, form a 5-7 membered heterocycle;
- R 3 1 is selected from the group consisting of deuterium, halide, -CN, -OH, amino, Ci_6 alkyl, C 3 -6 cycloalkyl, Ci_6 alkoxy, C2-6 alkynyl, C2-6 alkenyl, -S(Ci_6 alkyl), -NH(Ci_6 alkyl), -N(Ci_6 alkyl)2, aryl, 5-7 membered heteroaryl comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, and 5-7 membered heterocycle comprising 1-3 heteroatoms independently selected from the group consisting of O, N and S, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, Ci_6 alkoxy, aryl, heteroaryl, and heterocycle is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of deuterium, halide, -CN, -OH, amino, Ci_6 al
- the disclosed compound is according to Formula Ic:
- each of Zl, Z2 and Z3 is independently selected from the group consisting of O and
- each of R41 and R42 is independently selected from the group consisting of H, deuterium, halide and C1-3 alkyl.
- each of R19, R20, R21, R22, R25, R26, R27, R28, R29, and R30 is independently selected from the group consisting of H, deuterium, -CN, -OH, Ci_6 alkyl, C 3 -6 cycloalkyl, and C1-3 alkoxy, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, and C1-3 alkoxy is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, Ci_6 alkyl, and C1-3 alkoxy;
- each of R2 3 and R24 is independently selected from the group consisting of H, Ci_6 alkyl, and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, Ci_6 alkyl, and C1-3 alkoxy; or R22 and R2 3 , together with atoms they attached to, form a 5-7 membered heterocycle; and each of R and R' is independently selected from the group consisting of H, Ci_6 alkyl, C 3- 6 cycloalkyl, and C 3 -8 heterocycloalkyl comprising N or O, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, and C 3 -8 heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium,
- the disclosed compound is selected from the group consisting of:
- the disclosed compound is according to Formula II:
- R2 3 is selected from the group consisting of H, Ci_6 alkyl and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(Ci_6 alkyl), -N(C 1-6 alkyl) 2 , and Ci_ 3 alkoxy;
- Ci_ 6 alkyl, C 3 - 6 cycloalkyl, and C 3 -6 heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C 3 -6 cycloalkyl, C1-3 alkoxy, and C 3 -6 heterocycloalkyl comprising N or O; or R and R24, together with N atom they attached to, form a 5-7 membered heterocycle; and
- the disclosed compound is according to
- Ar is unsubstituted or substituted with 1-4 groups of R31 , and Ar is selected from the group consisting of:
- the disclosed compound is according to
- each of Di, D2 and D3 is independently selected from the group consisting of N and CR' 4 ;
- Ar is unsubstituted or substituted with 1-4 groups of R 3 1, and Ar is selected from the group consisting of:
- R2 3 is selected from the group consisting of H, Ci_6 alkyl, and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(Ci_6 alkyl), -N(C 1-6 alkyl) 2 , and Ci_ 3 alkoxy;
- Ci_ 6 alkyl and C 3 - 6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C 3 -6 cycloalkyl, C1-3 alkoxy, and C 3 -6 heterocycloalkyl comprising N or O; or R and R24, together with atoms they attached to, form a 5-7 membered heterocycle;
- R' is selected from the group consisting of H, Ci_6 alkyl, C 3 -6 cycloalkyl, and C 3 -8 heterocycloalkyl comprising N or O, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, and C 3 -8 heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, Ci_6 alkyl, C 3 -6 cycloalkyl, Ci-3 alkoxy; or R' and R21, together with atoms they attached to, form a 5-7 membered heterocycle.
- the disclosed compound is according to Formula III:
- each of Ai, A 2 , and A 3 is independently selected from the group consisting of N and CR44, wherein at least one of Ai, A 2 , and A 3 is N;
- each of R5 and R 6 is independently selected from the group consisting of H, deuterium, -CN, Ci-6 alkyl, and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(Ci_6 alkyl), -N(Ci_6 alkyf ,
- R 5 is O or CR ⁇ Rte, and R ⁇ and R5, together with atoms they attached to, form a ring;
- R 7 is selected from the group consisting of H, Ci_6 alkyl, C 3 -6 cycloalkyl, and C 3 -6 heterocycloalkyl comprising an O, wherein each of Ci_6 alkyl, C 3 -6 cycloalkyl, and C 3 -6 heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, C 3 -6 cycloalkyl, and C 3 -6 heterocycloalkyl comprising an O;
- each of Rg and R9 is independently selected from the group consisting of H, deuterium, -CN, Ci-6 alkyl, and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, and C1-3 alkoxy; or R 7 and Rg, and atoms attached thereto, form a ring;
- R44 is H, deuterium, halide, -CN, -OH, amino, Ci_6 alkyl, C 3 -6 cycloalkyl, Ci -8 alkoxy,
- R2 3 is selected from the group consisting of H, Ci_6 alkyl and C 3 -6 cycloalkyl, wherein each of Ci_6 alkyl and C 3 -6 cycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, amino, -NH(Ci_6 alkyl), -N(C 1-6 alkyl) 2 , and Ci_ 3 alkoxy;
- each of R and R24 is independently selected from the group consisting of H, Ci_6 alkyl,
- Ci_ 6 alkyl, C 3 - 6 cycloalkyl, and C 3 -6 heterocycloalkyl is unsubstituted or substituted with 1-3 groups independently selected from the group consisting of halide, deuterium, -OH, -CN, C 3 -6 cycloalkyl, C1-3 alkoxy, and C 3 -6 heterocycloalkyl comprising N or O; or R and R24, together with N atom they attached to, form a 5-7 membered heterocycle; or R and R21, together with N atom they attached to, form a 5-7 membered heterocycle;
- each of R45 and R 3 ⁇ 4 is independently selected from the group consisting of H, deuterium, halide, C1-3 alkyl; or R45 and R4 6 , together with the atoms they attached to, form a ring.
- the disclosed compound is according to
- each of Ei, E 2 , and E3 is independently selected from the group consisting of O and
- each of R45 and R 3 ⁇ 4 is independently selected from the group consisting of H, deuterium, halide, C1-3 alkyl; or R45 and R4 6 , together with the atoms they attached to, form a ring.
- the disclosed compound is according to formula Ilia and Illb, and each of Ei, E 2 , and E 3 is independently selected from the group
- the disclosed compound is according to formula Ilia and Illb, and each of Ai and A2 is independently selected from the group consisting of N and CR44, wherein at least one of Ai and A2 is N;
- -C(R5R 6 )W2 is selected from the group consisting of:
- U is unsubstituted or substituted with is unsubstituted or substituted with 1-3 groups selected from the group consisting of deuterium, halide, -OH, C1-3 alk l, and C1-3 alkox , and U is selected from the rou consistin of:
- Another aspect of the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of formulas I, la, lb, Ic, II, Ila, lib, III, Ilia, and Illb or other compounds disclosed herein, or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or tautomer thereof, and a pharmaceutically acceptable carrier, diluent, adjuvant or excipient.
- Another aspect of the present disclosure provides a combination composition comprising:
- Another aspect of the present disclosure provides a compound of formulas I, la, lb, Ic, II,
- FIG. 1 depicts the 12G5 assay by compound A42.
- FIG. 2 depicts the 12G5 assay by compound A43.
- FIG. 3 depicts the 12G5 assay by compound A78.
- FIG. 4 depicts the 12G5 assay by compound A83.
- alkyl generally refers to a straight or branched chain saturated aliphatic hydrocarbon.
- Alkyl groups include groups having from 1 to 8 carbon atoms (Ci-C 8 alkyl), from 1 to 6 carbon atoms (Ci-C 6 alkyl) and from 1 to 4 carbon atoms (Ci-C 4 alkyl), including, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, icri-butyl, pentyl, 2- pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl and 3-methylpentyl.
- a substituent of an alkyl group is specifically indicated.
- cyanoalkyl refers to an alkyl group substituted with at least one cyano substituent.
- alkenyl as used herein generally refers to straight or branched chain alkene groups, which comprise at least one unsaturated carbon-carbon double bond.
- Alkenyl groups include C2-C 8 alkenyl, C2-C 6 alkenyl and C2-C4 alkenyl groups, which have from 2 to 8, 2 to 6 or 2 to 4 carbon atoms, respectively, including, for example, ethenyl, allyl or isopropenyl.
- alkynyl as used herein generally refers to straight or branched chain alkyne groups, which have one or more unsaturated carbon-carbon bonds, at least one of which is a triple bond.
- Alkynyl groups include C2-C 8 alkynyl, C2-C 6 alkynyl and C2-C4 alkynyl groups, which have from 2 to 8, 2 to 6 or 2 to 4 carbon atoms, respectively.
- cycloalkyl as used herein generally refers to a group that comprises one or more saturated rings in which all ring members are carbon, including, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl. Cycloalkyl groups do not comprise an aromatic ring or a heterocyclic ring. For example, certain cycloalkyl groups are
- cycloalkyl in which the cycloalkyl group contains a single ring having from 3 to 7 ring members, all of which are carbon.
- cycloalkenyl as used herein generally refers to a group that comprises one or more unsaturated rings in which all ring members are carbon.
- alkoxy generally refers to an alkyl group as described above attached via an oxygen bridge.
- Alkoxy groups include Ci-C 6 alkoxy and C1-C4 alkoxy groups, which have from 1 to 6 or from 1 to 4 carbon atoms, respectively.
- Methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, seobutoxy, i ⁇ ?ri-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy are representative alkoxy groups.
- alkylamino generally refers to a secondary or tertiary amine that has the general structure -NH-R1 or -N(R1)(R2), wherein Rl and R2 are selected independently from alkyl, cycloalkyl and (cycloalkyl)alkyl groups.
- groups include, but are not limited to, for example, mono- and di-(Ci-C6 alkyl)amino groups, in which each Ci-C 6 alkyl may be the same or different.
- alkyl as used in the term “alkylamino” differs from the definition of "alkyl” used for all other alkyl-containing groups, in the inclusion of cycloalkyl and (cycloalkyl)alkyl groups.
- alkylthio as used herein generally refers to an alkyl-substituted thio group, wherein the term alkyl is as defined above.
- halogen or "halide” as used herein generally refers to fluorine, chlorine, bromine, and iodine.
- haloalkyl as used herein generally refers to an alkyl group that is substituted with one or more independently chosen halogens (e.g., "Ci-C 6 haloalkyl” groups have from 1 to 6 carbon atoms and at least one halogen).
- haloalkyl groups include, but are not limited to, mono-, di- or tri-fluoromethyl; mono-, di- or tri-chloromethyl; mono-, di-, tri-, tetra- or penta-fluoroethyl; mono-, di-, tri-, tetra- or penta-chloroethyl; and 1,2,2,2- tetrafluoro-l-trifluoromethyl-ethyl.
- heteroaryl as used herein generally refers to an aromatic group in which at least one aromatic ring comprises at least one heteroatom selected from N, O and S.
- Heteroaryls include, for example, 5-12 membered heteroaryls. Examples include, but are not limited to, imidazole, furan, furazan, isothiazole, isoxazole, oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, tetrazole, thiazole and thiophene.
- heterocycloalkyl as used herein generally refers to a ring structure containing
- 3-12 ring atoms in which in which at least one ring atom is carbon and at least one ring atom is heteroatom selected from N, O, and S.
- examples include, but are not limited to, aziridine, oxiran, thiirane, azetidine, oxetane, thietane, pyrrolidine, tetrahydrofuran, and
- heterocyclic or “heterocycle” as used herein generally refers to a ring structure containing 3-12 ring atoms, in which at least one ring atom is carbon and at least one ring atom is heteroatom selected from N, O, and S.
- a heterocyclic group may be aromatic or non-aromatic.
- Piperidine and oxetane are non-limiting examples of non-aromatic heterocycles.
- Thiazole and pyridine are non-limiting examples of aromatic heterocycles.
- substituted and “substituted,” as used herein, generally denote that a molecular moiety is covalently bonded to an atom within a molecule of interest.
- a ring substituent may be a moiety such as a halogen, alkyl group, haloalkyl group or other group that is covalently bonded to an atom (preferably a carbon or nitrogen atom) that is a ring member.
- Substituents of aromatic groups are generally covalently bonded to a ring carbon atom.
- a straight chain substituent may be a moiety such as a halogen, alkyl group, haloalkyl group or other group that is covalently bonded to an atom (preferably a carbon or nitrogen atom) that is a member of a straight chain.
- pharmaceutically acceptable generally refers to a form of the compound that is safe for administration to a subject.
- a free base, a salt form, a solvate, a hydrate, a prodrug or derivative form of a compound of formula I which has been approved for mammalian use, via oral ingestion or any other route of administration, by a governing authority or regulatory agency, such as the Food and Drug Administration (FDA) of the United States, is pharmaceutically acceptable.
- FDA Food and Drug Administration
- salts generally refers to salts, commonly used to form alkali metal salts and to form addition salts of free acids or free bases, which have been approved by a regulatory agency. Salts are formed from ionic associations, charge-charge interactions, covalent bonding, complexation, coordination, etc. The nature of the salt is not critical, provided that it is pharmaceutically acceptable.
- the compound(s) of formulas I, la, lb, Ic, II, Ila, lib, III, Ilia, and Illb is used to treat a subject by administering the compound(s) as a pharmaceutical composition.
- the compound(s) in one embodiment, is combined with one or more pharmaceutically acceptable excipients, including carriers, diluents or adjuvants, to form a suitable composition, which is described in more detail herein.
- excipient generally refers to any pharmaceutically acceptable additive, carrier, adjuvant, or other suitable ingredient, other than the active pharmaceutical ingredient (API), which is typically included for formulation and/or administration purposes.
- diluent generally refers to an agent used as filler in order to achieve the desired composition volume or weight.
- the diluent may be present in the pharmaceutical composition within granules in the form of a single compound or in the form of a mixture of compounds.
- Non-limiting examples of diluent include lactose, starch,
- pregelatinized starch microcrystalline cellulose, silicified microcrystalline cellulose, cellulose acetate, dextrose, mannitol, sodium phosphate, potassium phosphate, calcium phosphate, fructose, maltose, sorbitol, or sucrose.
- adjuvant generally refers to any substance or mixture of substances that increases the efficacy or potency of a compound disclosed herein on a target where the adjuvant is used together with the compound disclosed herein. However, when the adjuvant is used alone, no pharmacological effect is observed on the same target.
- the terms “treat”, “treating,” “treatment,” and “therapy” as used herein generally refer to therapy, including without limitation, curative therapy, prophylactic therapy, and preventative therapy.
- Prophylactic treatment generally constitutes either preventing the onset of disorders altogether or delaying the onset of a pre-clinically evident stage of disorders in individuals.
- the phrase "effective amount” as used herein generally refers to quantifying the amount of each agent, which will achieve the goal of improvement in disorder severity and the frequency of incidence over treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative therapies.
- the effective amount in one embodiment, is administered in a single dosage form or in multiple dosage forms.
- the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms or by other conventional methods known to those of skill in the art.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an effective amount of the active ingredient to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular hedgehog inhibitor employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
- the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
- a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous, intracerebroventricular and subcutaneous doses of the compounds of this invention for a patient will range from about 0.0001 to about 100 mg per kilogram of body weight per day. The mode of administration can have a large effect on dosage. Higher doses may be used for localized routes of delivery.
- the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
- dose levels can vary as a function of the specific compound, the severity of the symptoms and the susceptibility of the subject to side effects. Dosages for a given compound disclosed herein are readily determinable by those of skill in the art by a variety of means.
- One embodiment provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula I, or a stereoisomer, tautomer, hydrate, solvate or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
- the compounds described herein are formulated into
- compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- a summary of pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed., Easton, Pa.: Mack Publishing Company (1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania (1975); Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y.
- a pharmaceutical composition refers to a mixture of a compound of formula I with other chemical components (i.e. pharmaceutically acceptable inactive ingredients), such as carriers, excipients, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or more combination thereof.
- pharmaceutically acceptable inactive ingredients such as carriers, excipients, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or
- the pharmaceutical composition facilitates administration of the compound to an organism.
- therapeutically effective amounts of compounds described herein are administered in a pharmaceutical composition to a mammal having a disease, disorder, or condition to be treated.
- the mammal is a human.
- a therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors.
- the compounds can be used singly or in combination with one or more therapeutic agents as components of mixtures.
- the pharmaceutical formulations described herein are administered to a subject by appropriate administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal administration routes.
- the pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
- dosage units are tablets or capsules. In some embodiments, these contain an amount of active ingredient from about 1 to 2000 mg, advantageously from about 1 to 500 mg, and typically from about 5 to 150 mg.
- a suitable daily dose for a human or other mammal vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods and practices.
- Conventional formulation techniques include, e.g., one or a combination of methods: (1) dry mixing, (2) direct compression, (3) milling, (4) dry or non-aqueous granulation, (5) wet granulation, or (6) fusion.
- Other methods include, e.g., spray drying, pan coating, melt granulation, granulation, fluidized bed spray drying or coating (e.g., wurster coating), tangential coating, top spraying, tableting, extruding and the like.
- Methods of the present invention may include the use of at least one compound of
- Formulas I, la, lb, Ic, II, Ila, lib, III, Ilia, and Illb which inhibits necrosis in the regulation of repair and/or functional performance of a wide range of cells, tissues and organs, and have therapeutic and cosmetic applications ranging from regulation of neural tissues, bone and cartilage formation and repair, regulation of spermatogenesis, regulation of smooth muscle, regulation of lung, liver and other organs arising from the primitive gut, regulation of hematopoietic function, regulation of skin and hair growth, etc.
- the methods and compositions of the present invention include the use of the subject inhibitors for all such uses as inhibitors of necrosis may be implicated.
- the subject methods can be performed on cells which are provided in culture (in vitro), or on cells in a whole animal (in vivo).
- the compounds of the present invention can be prepared using various synthetic routes, including those described below, starting from commercially available materials.
- Starting materials of the invention are either known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art. Many starting materials may be prepared according to known processes and, in particular, can be prepared using processes described in the examples. In synthesizing starting materials, functional groups in some cases are protected with suitable protecting groups when necessary. Functional groups may be removed according to known procedures in the art.
- the invention further encompasses "intermediate" compounds, including structures produced from the synthetic procedures described, whether isolated or not, prior to obtaining the finally desired compound. Structures resulting from carrying out steps from a transient starting material, structures resulting from divergence from the described method(s) at any stage, and structures forming starting materials under the reaction conditions are all "intermediates" included in the invention. Further, structures produced by using starting materials in the form of a reactive derivative or salt, or produced by a compound obtainable by means of the process according to the invention and structures resulting from processing the compounds of the invention in situ are also within the scope of the invention.
- New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention. In select embodiments, such starting materials are used and reaction conditions so selected as to obtain the desired compound(s).
- Starting materials of the invention are either known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art. Many starting materials may be prepared according to known processes and, in particular, can be prepared using processes described in the examples. In synthesizing starting materials, functional groups in some cases are protected with suitable protecting groups when necessary. Protecting groups, their introduction and removal are described above.
- a work-up involves generally quenching of a reaction to terminate any remaining catalytic activity and starting reagents. This is generally followed by addition of an organic solvent and separation of the aqueous layer from the organic layer. The product is typically obtained from the organic layer and unused reactants and other spurious side products and unwanted chemicals are generally trapped in the aqueous layer and discarded.
- the work-up in standard organic synthetic procedures found throughout the literature is generally followed by drying the product by exposure to a drying agent, such as anhydrous Na 2 S0 4 , to remove any excess water or aqueous byproducts remaining partially dissolved in the organic layer and concentration of the remaining organic layer.
- Concentration of product dissolved in solvent may be achieved by any known means, such as evaporation under pressure, evaporation under increased temperature and pressure, and the like. Such concentrating may be achieved by use of standard laboratory equipment such as rotary-evaporator distillation, and the like. This is optionally followed by one or more purification steps which may include, but is not limited to, flash column
- the compounds of the present invention can be prepared using various synthetic routes, including those described by methods A-N, BA-BS and AA-AT below, starting from
- Starting materials of the invention are either known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art. Many starting materials may be prepared according to known processes and, in particular, can be prepared using processed described in the methods and examples. In synthesizing starting materials, functional groups in some cases are protected with suitable protecting groups when necessary. Functional groups may be removed according to known procedures in the art.
- chloropyrimidine may be achieved with POCl 3 (step b).
- Step a Substituted 4-chloro-3-oxobutanoate could also be reacted with amidine and DBU to give the pyrimidine intermediate (step a). Conversion of the hydroxypyrimidine to the chloropyrimidine may be achieved with POCl 3 (step b).4-aminopyrimidine core may be synthesized via methyl amine substitution (step c) followed by condensation of
- Pyrimidine-4-carbaldehyde core could be synthesized via cyclization to the pyrimidine core (step a) followed by condensation of hydroxypyrimidine with corresponded amine (step b), following hydrolysis (step c).
- the key intermediate 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2- (methylthio)pyrimidine may be formed via cyclization followed condensation 6- (dimethoxymethyl)-2-(methylthio)pyrimidin-4-ol with 1-methylpiperazine (step b) .
- 2- subsituted Pyrimidine-4-carbaldehyde core could be synthesized via oxidation of methyl sulfide to methylsulfonyl (step c), substitution with corresponding alcohol (step f) or amine (step d) followed by hydrolysis (step e, g) or can be formed by Suzuki coupling (step h) followed hydrolysis (step i).
- the targeted compounds may be formed via cyclization (step a) followed condensation hydroxypyrimidine with 1-methylpiperazine (step b), following substitution with corresponding amine (step c).
- 4-(4-methylpiperazin- l-yl)pyrimidine core can be achieved by condensation the amino acid with 2,2-dimethyl-l ,3-dioxane-4,6-dione followed decarboxylation (step a); following cyclization (step b) followed condensation hydroxypyrimidine with 1-methylpiperazine (step c) and at last de-Boc protective group (step c).
- step a W n 0 ⁇ ⁇
- heteroaromatic core could be substituted with bromine treated with NBS and free radical initiator.
- the 2-methyl-5-nynaopyrimidine core may be achieved by cyclization (step a) followed condensation hydroxypyrimidine with corresponding amine (step b), following chlorination (step c) and substitution with corresponding amine (step d).
- 5-bromo-2-(bromomethyl)imidazo[l,2-a]pyridine may be synthesized by 6- bromopyridin-2-amine cyclization with ethyl 3-bromo-2-oxopropanoate (step a), and then followed by reduction with NaBH 4 (step b) and bromination with PBr 3 (step c).
- the targeted core can be synthesized via the reductive amination(step a, b) with the ketone, or followed the reductive amination(step c) again with the aldehyde, then de- protective group treated with TFA (step d).
- the targeted core may be achieved by chlorination (step a) with TCCA and substitution with corresponding amine (step b).
- the intermediate l-(3-aminopyridin-2-yl)ethan-l-one may be formed by substitution with (4-methoxyphenyl)methanamine (step a) followed Grignard reaction using CHsMgCl (step b), then de-PMB group with TFA (step c).
- the targeted compounds can be obtained by acylation (step c) or mesylation (step d).
- step e The 2-(pyrrolidin-2-yl)pyridine(S/R) can be formed by Grignard reaction with picolinonitrile and hydrolysis (step a), following the reductive animation with (4- methoxyphenyl)ethan-l-amine (R/S) (step b, d), then de-protective group treated with TFA (step c, e).
- racemic 2-(3-methylpyrrolidin-2-yl)pyridine may achieved by imidization catalysis by TsOH (step a) followed Michael addition reaction treatment with ethyl (E)-but-2- enoate (step b), following formation lactam with con. HCl (step c), then reduction using L1AIH 4 (step d).
- the Picolinaldehyde may be reacted with aminoacetonitrile to generate the Schiff base.
- Pyrrole ring could be made via a [3 + 2] cyclization.
- the cyano group could be knock out by a series of reductive reaction.
- the substituted 8-nitroquinoline can be formed by cyclization treatment gly with 2-nitroaniline (step a), then substituted 8-nitroquinoline was reduced to the 8- aminoquinoline core with Pd/C(step b).
- the 8-aminoquinolinecore could be methylated using methyl iodide.
- the quinoline containing core can be formed by cyclization treatment gly with 2-fluoroaniline (step a)and substitution with corresponding amine (step b).
- the PMB protective group could be removed under the acid condition.
- 8-chloro-l,7-naphthyridine can be formed via cyclization (step a), then chlorination through Sandmeyer reaction (step b).
- step a step b
- 8-bromo-l,6-naphthyridine can be formed via cyclization (step a), then bromination with bromine.
- step a step b
- step a step b
- the finally targeted compounds can be obtained by substitution the chlorine of 4- chloro-6-(chloromethyl)pyrimidine with corresponding amines respectively (step a, b).
- step a step b
- the finally targeted compounds can be obtained by substitution the chlorine of 4- chloropyrimide core with N-Boc-piperazine (step a) followed de-Boc group treatment with acid (step b), following Michael addition reaction treatment with acrylonitrile (step c).
- the finally targeted compounds may be formed by reduced animation using NaBH(OAc) 3 or NaBH 3 CN (step a).
- the finally targeted compounds may be formed by de-Boc group under acid condition (step a) followed reduced amination using NaBH(OAc)3 or NaB]3 ⁇ 4CN (step b).
- the finally targeted compounds can be obtained by substitution the bromine of 4- (bromomethyl)-6-chloropyrimidine with corresponding amines firstly (step a), then substitution the chlorine of 6-chloropyrimidine with corresponding amines (step b).
- heteroaromatic derivatives could be synthesized via the reductive amination (step a)followed by substitution with corresponding amine (step b).
- the (2-methylpyrimidin-5-yl)methanol containing targeted compounds could be synthesized from 2-methylpyrimidine-4,6-diol.
- the Vilsmeier-Haack reaction with DMF and POCI 3 (step a) followed by reduction aldehyde to alcohol with NaBH 4 (step a); protection of the alcohol group with TBSCI (step b), and then home reaction with trifluoroborate(step c).
- Oxidation of the double bind to aldehyde with ozone step c
- the reductive animation step d
- step e the reductive animation followeded by displacement of the pyrimidine chlorine with corresponding amines
- the TBS protective group could be removed under the acid condition.
- methyl ester of quinoline core could be reduced to alcohol by NaBH 4 or LiAlH 4 .
- step b ⁇ ⁇ step c ⁇
- the finally targeted compounds can be obtained by substitution the bromine of 5- bromo-2-(bromomethyl)imidazo[l,2- ]pyridine with corresponding amines firstly (step a) followed by substitution the bromine of 5-bromoimidazo[l,2- ]pyridine core with 1- methylpiperazine(step b), following introduction of hydroxymethyl group at 3-position of imidazo[l,2-a]pyridine core under formaldehyde condition (step 3).
- the finally targeted compound can be synthesized by fluorination of the commercially 6,7-dihydroquinolin-8(5H)-one using selectfluoro (step a), then the reduced amination of ketone with methyl amine (step b), following by alkylation with 4-chloro-6- (chloromethyl)-2-methylpyrimidine (step c), and finally substitution withl- methylpiperazine(step d).
- the finally targeted compounds may be formed by reduced amination with corresponding aldehydes using NaBH(OAc)3 or NaB]3 ⁇ 4CN (step a).
- the finally targeted compounds may be formed by substitution with aryl halogen under base, high temperature condition (step a).
- the finally targeted compounds may be formed by Buchwald coupling reaction with aryl halogen Pd 2 (dba) 3 , BINAP, Cs 2 C0 3 condition (step a).
- the finally targeted compound may be formed by de-Boc group under the acid condition (step a) followed condensation using HATU (step b).
- the halogen of quinoline core could be converted to cyano group under the condition of Pd(PPh 3 ) 4 , dppf, and zinc cyanide or Pd 2 (dba) 3 , dppf, and zinc cyanide.
- the finally targeted compounds could be synthesized from 8-fluoroquinoline.
- the nitrification with HNO 3 step a) followed by displacement of the aryl fluorine with corresponding amines (step b).
- the nitro group can be reduced to the amino group with SnCl 2 (step c) and then mesylation with MsCl (step d).
- Step a 6-(chloromethyl)-2-(methylthio)pyrimidin-4-ol: To a solution of ethyl 4- chloro-3- oxobutanoate (13 g, 79 mmol) and methyl carbamimidothioatesulphate (20 g, 72 mmol) in water (200 mL) was added sodium carbonate (11.5 g, 108 mmol). The reaction was stirred at room temperature overnight. The mixture was quenched with 6M HC1 aqueous solution to pH acid and filtered. The filter cake was dried to give the desired product (11.1 g,
- H NMR 400 MHz, CDC1 3 ) ⁇ 7.23 (s, IH), 4.53 (s, 2H), 2.58 (s, 3H).
- Step a 6-(chloromethyl)-2-methylpyrimidin-4-ol: To a solution of ethyl 4-chloro- 3- oxobutanoate (16.5 g, 100 mmol) and acetamidine hydrochloride (10 g, 106 mmol) in ethanol (150 mL) was slowly added DBU (30.4 g, 200 mmol) at 4 °C. The reaction was stirred at room temperature overnight. The reaction mixture was concentrated and the residue was dissolved in dichloromethane (120 mL), then washed with brine (30 mL x 3). The organic layer was dried over Na 2 S0 4 and concentrated to give the desired product (7.93 g, 50%) as a yellow oil.
- H NMR 400 MHz, CDC1 3 ) ⁇ 13.01 (s, 1H), 6.53 (s, 1H), 4.37 (s, 2H), 2.50 (s, 3H).
- Step b 4-chloro-6-(chloromethyl)-2-methylpyrimidine: The solution of 6- (chloromethyl)-2- methylpyrimidin-4-ol (7.93 g, 50 mmol) in POCI 3 (20 mL) was heated to 110 °C, and stirred for 30 min. Then reaction mixture was concentrated and dissolved in ethyl acetate (20 mL), then added this solution into ice water (100 mL), extracted with ethyl acetate (30 mL x 3). The combined organic layer was dried over Na 2 S0 4 and concentrated.
- Step c. 2-methyl-6-((methylamino)methyl)pyrimidin-4-ol The solution of 6- (chloromethyl)-2- methylpyrimidin-4-ol (1.7 g, 11 mmol), methylamine solution (30 wt percent in absolute ethanol, 3 g), KI (183 mg, 1.1 mmol) and DIPEA (7.1 g, 55 mmol) in CH 3 CN (50 mL) was added into a sealed tube, and heated to 60 °C. The reaction was stirred at this temperature overnight.
- Step d N-methyl-l-(2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin-4- yl)methanamine: To a solution of 2-methyl-6-((methylamino)methyl)pyrimidin-4-ol (300 mg, 1.96 mmol), TEA (1.9 g, 19.6 mmol) and N-methylpiperazine (980 mg, 9.8 mmol) in CH 3 CN (20 mL) was added PyBOP (1.1 g, 2.15 mmol). The reaction mixture was stirred at reflux overnight.
- Step b 4-(dimethoxymethyl)-2-methyl-6-(4-methylpiperazin-l-yl)pyrimidine: To a solution of 6-(dimethoxymethyl)-2-methylpyrimidin-4-ol (110 mg, 0.6 mmol), TEA (600 mg, 6 mmol) and N-methylpiperazine (90 mg, 0.9 mmol) in CH 3 CN (10 mL) was added PyBOP (340 mg, 0.7 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction solution was evaporated to remove most of CH 3 CN, added saturated NaHCC>3 aqueous solution (100 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
- Step c. 2-methyl-6-(4-methylpiperazin-l-yl)pyrimidine-4-carbaldehyde The mixture of 4-(dimethoxymethyl)-2-methyl-6-(4-methylpiperazin-l-yl)pyrimidine (140 mg, 0.5 mmol) and sulfuric acid (20 wt percent in water, 5 mL) was stirred at reflux overnight. Then the saturated NaHCC>3 aqueous solution was added to adjust pH to basic and extracted with dichloromethane (100 mL x 3). The combined organic layer was dried over Na 2 S0 4 , filtered and evaporated to give the crude desired product (110 mg, 97%) as a yellow oil.
- Step a 6-(dimethoxymethyl)-2-(methyltliio)pyrimidin-4-ol: To a solution of methyl 4,4-dimethoxy-3-oxobutanoate (3 g, 17 mmol) and methyl carbamimidothioatesulphate (9.5 g, 34 mmol) in water (100 mL) was added K 2 CO 3 (17.6 g, 76.5 mmol). The reaction was stirred at room temperature overnight. The mixture was quenched with AcOH to adjust pH to acid and extracted with dichloromethane (100 mL x 3). The combined organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column
- Step b 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2- (methylthio)pyrimidine: To a solution of 6-(dimethoxymethyl)-2-(methylthio)pyrimidin-4-ol (3.4 g, 16 mmol), TEA (16 g, 160 mmol) and N-methylpiperazine (2.4 g, 40 mmol) in CH 3 CN (100 mL) was added PyBOP (9g, 17.6 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction solution was evaporated to remove most of CH 3 CN, added saturated NaHCC>3 aqueous solution (200 mL) and extracted with dichloromethane (200 mL).
- Step c 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2- (methylsulfonyl)pyrimidine: To a solution of 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)- 2-(methylthio)pyrimidine (2.8 g, 9.4 mmol) in THF (90 mL) and water (4.5 mL) was added Oxone (7 g, 11 mmol). The reaction was stirred at room temperature for 4h. Then the reaction was added saturated NaHCC>3 aqueous solution (200 mL) and extracted with ethyl acetate (200 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated to give the desired product (2.4 g, 78%) as a yellow oil.
- Step d 4-(dimethoxymethyl)-N,N-dimethyl-6-(4-methylpiperazin-l-yl)pyrimidin- 2-amine: To a solution of 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2- (methylsulfonyl)pyrimidine (340 mg, 1 mmol) in THF (5 mL) in a sealed tube was added dimethylamine (5 mL). The reaction mixture was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, added saturated NaHCC>3 aqueous solution (100 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
- Step e 2-(dimethylamino)-6-(4-methylpiperazin-l-yl)pyrimidine-4-carbaldehyde: The mixture of 4-(dimethoxymethyl)-N,N-dimethyl-6-(4-methylpiperazin-l-yl)pyrimidin-2- amine (260 mg, 1.3 mmol) and sulfuric acid(20 wt percent in water, 5 mL) was stirred at reflux overnight. Then the saturated NaHCC>3 aqueous solution was added to adjust pH to basic and extracted with dichloromethane (100 mL x 3).
- Step f 4-(dimethoxymethyl)-2-ethoxy-6-(4-methylpiperazin-l-yl)pyrimidine: To a solution of 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2-(methylsulfonyl)pyrimidine (200 mg, 0.61 mmol) in ethanol (5 mL) was added sodium ethanolate (206 mg, 3 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, added saturated NaHCC>3 aqueous solution (100 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
- Step g. 2-ethoxy-6-(4-methylpiperazin-l-yl)pyrimidine-4-carbaldehyde The mixture of 4-(dimethoxymethyl)-2-ethoxy-6-(4-methylpiperazin-l-yl)pyrimidine (160 mg, 0.5 mmol) and sulfuric acid (20 wt percent in water, 5 mL) was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, and the saturated NaHCC>3 aqueous solution was added to adjust pH to basic and extracted with dichloromethane (100 mL x 3). The combined organic layer was dried over Na 2 S0 4 , filtered and evaporated to give the crude desired product (100 mg, 80%) as a yellow solid.
- Step h 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2-phenylpyrimidine: The mixture of 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2-(methylthio)pyrimidine (298 mg, 1 mmol), phenylboronic acid (244 mg, 2 mmol), copper(I) thiophene-2-carboxylate (497 mg, 2.6 mmol) and Pd(PPh 3 ) 4 (115 mg, 0.1 mmol) in THF (20 mL) was stirred at reflux overnight under N 2 atmosphere.
- Step i 6-(4-methylpiperazin-l-yl)-2-phenylpyrimidine-4-carbaldehyde: The mixture of 4-(dimethoxymethyl)-6-(4-methylpiperazin-l-yl)-2-phenylpyrimidine (240 mg, 0.73 mmol) and sulfuric acid (20 wt percent in water, 10 mL) was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, and washed with diethyl ether (10 mL). The water phase was added 6M NaOH aqueous solution to adjust pH to 10 and extracted with dichloromethane (30 mL x 3). The combined organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
- Step a ethyl 2,4-difluoro-3-oxobutanoate: To a solution of NaH (60 wt percent moistened with oil, 936 mg, 23.4 mmol) in diethyl ether (50 mL) was added dropwise ethyl 2- fluoroacetate (5 g, 47.2 mmol) at room temperature. The reaction was stirred at 40°C for 4h. The reaction mixture was cooled to 0°C and poured into 2M sulfuric acid aqueous solution (15 mL). The mixture was extracted with diethyl ether (50 mL x 3). The combined organic layer was dried over Na2S0 4 , filtered and evaporated. The residue was purified by silica gel column
- Step b 5-fluoro-6-(fluoromethyl)-2-methylpyrimidin-4-ol: To a solution of methyl 4,4-dimethoxy- 3-oxobutanoate (1.9 g, 11.4 mmol) and acetamidine hydrochloride (2.2 g, 22.8 mmol) in ethanol (40 mL) was added EtONa (2.3 g, 34.2 mmol). The reaction was stirred at reflux overnight. The mixture was cooled to room temperature. 6M HC1 aqueous solution (2 mL) was added and evaporated.
- Step c. 5-fluoro-4-(fluoromethyl)-2-methyl-6-(4-methylpiperazin-l- yl)pyrimidine To a solution of 5-fluoro-6-(fluoromethyl)-2-methylpyrimidin-4-ol (800 mg, 5 mmol), TEA (1.5 g, 15 mmol) and N-methylpiperazine (750 mg, 7.5 mmol) in C3 ⁇ 4CN (10 mL) was added PyBOP (2.9 g, 5.5 mmol). The reaction mixture was stirred at reflux overnight.
- Step d l-(5-fluoro-2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin-4-yl)-N- methylmethanamine: The mixture of 5-fluoro-4-(fluoromethyl)-2-methyl-6-(4-methylpiperazin- l-yl)pyrimidine (1.0 g, 4.1 mmol) and 2M methyl amine (in methanol, 6 mL) in water (15 mL) and i-propanol (15 mL) in a sealed tube was stirred at reflux overnight. The reaction solution was evaporated to remove most of i-propanol, and extracted with dichloromethane (30 mL x 3).
- Step a (5)-tert-butyl 2-(3-ethoxy-3-oxopropanoyl)pyrrolidine-l-carboxylate: To a mixture of Boc-L-Proline-OH (5 g, 23 mmol), 2,2-dimethyl-l,3-dioxane-4,6-dione (3.4 g, 23 mmol) and DMAP (5.7 g, 46 mmol) in dichloromethane (70 mL) was added DCC (4.8 g, 23 mmol) at 0 °C. The mixture was stirred at room temperature for 48 h before the reaction mixture was filtered.
- Step b (5)-tert-butyl 2-(6-hydroxy-2-(methylthio)pyrimidin-4-yl)pyrrolidine-l- carboxylate: To a solution of (5)-tert-butyl 2-(3-ethoxy-3-oxopropanoyl)pyrrolidine-l- carboxylate (500 mg, 1.8 mmol) and methyl carbamimidothioatesulphate (1.0 g, 3.6 mmol) in water (25 mL) was added K 2 CO 3 (1.1 g, 8.1 mmol). The reaction was stirred at room
- Step c. (5)-4-(4-methylpiperazin-l-yl)-2-(methylthio)-6-(pyrrolidin-2- yl)pyrimidine To a solution of (S)-tert-butyl 2-(6-hydroxy-2-(methylthio)pyrimidin-4- yl)pyrrolidine-l-carboxylate (200 mg, 0.64 mmol), TEA (650 mg, 6.4 mmol) and N- methylpiperazine (100 mg, 0.96 mmol) in CH 3 CN (5 mL) was added PyBOP (510 mg, 0.96 mmol). The reaction mixture was stirred at reflux overnight.
- reaction solution was evaporated to remove most of CH 3 CN, added dichloromethane (100 mL) to dilute, washed with saturated NaHCC>3 aqueous solution (100 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
- Step a i ⁇ ?ri-butyl 5-oxo-5-(pyridin-2-yl)pentylcarbamate: To a THF solution (30 mL) containing commercially available 2-bromopyridine (1.4 g, 9 mmol) and ⁇ , ⁇ , ⁇ '- ⁇ '- tetramethyl ethylene diamine (960 mg, 6.5 mmol), a hexane solution (3 mL, 7.5 mmol) of 2.5M n-butyl lithium was added dropwise at -78°C, and the resulting solution was stirred at the same temperature for 2h.
- tert-butyl 2-oxopiperidine-l-carboxylate (1 g, 5 mmol) was added at -78°C, and the resulting solution was stirred at the same temperature for 2h.
- water (10 mL) was added, and the solution was extracted with ethyl acetate (100 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated.
- Step a 2-(bromomethyl)-4-chloropyrimidine: To a solution 4-chloro-2- methylpyrimidine (370 mg, 2.9 mmol), NBS (566 mg, 3.2 mmol) and AIBN (50 mg, 0.3 mmol) in CC1 4 (10 mL) was stirred at reflux overnight. Then the reaction solution was cooled to room temperature, added saturated NaHCC>3 aqueous solution (50 mL) and extracted with
- Step a 4-hydroxy-2,6-dimethylpyrimidine-5-carbonitrile: To a solution of methyl (Z)-ethyl 2-cyano-3-ethoxybut-2-enoate (5.0 g, 27 mmol) and acetamidine hydrochloride (3.9 g, 41 mmol) in ethanol (80 mL) was added K 2 CO 3 (11.3 g, 82 mmol). The reaction was stirred at room temperature overnight. The mixture was concentrated, added 3M HCl aqueous solution to adjust pH to 5 and extracted with n-butanol (50 mL x 6). The combined organic layer was evaporated to give the desired product (3.5 g, 87%) as a yellow solid. ! H NMR (400 MHz, DMSO-i3 ⁇ 4) ⁇ 13.30 (s, 1H), 2.39 (s, 3H), 2.35 (s, 3H).
- Step b feri-butyl 4-(5-cyano-2,6-dimethylpyrimidin-4-yl)piperazine-l- carboxylate: To a solution of 4-hydroxy-2,6-dimemylpyrimidine-5-carbonitrile (2.5 g, 16.8 mmol), TEA (5.1 g, 50.4 mmol) and i ⁇ ?ri-butyl piperazine-l-carboxylate (4.7 g, 25.2 mmol) in CH 3 CN (60 mL) was added PyBOP (9.6 g, 18.5 mmol). The reaction mixture was stirred at reflux overnight. Then the reaction solution was evaporated.
- Step c. i ⁇ ?ri-butyl 4-(6-(chloromethyl)-5-cyano-2-methylpyrimidin-4- yl)piperazine-l-carboxylate A mixture of feri-butyl 4-(5-cyano-2,6-dimethylpyrimidin-4- yl)piperazine-l-carboxylate (10 g, 60 4.0 g, 12.6 mmol) in DCM (100 mL) was added TCCA (2.9 g, 12.6 mmol) at 0°C, and the resulting solution was stirred at the same temperature for lh, then stirred at room temperature for 6h.
- TCCA 2.9 g, 12.6 mmol
- the reaction was quenched with the saturated Na 2 S 2 0 3 aqueous solution.
- the reaction mixture was filtered and the filtrate was extracted with dichloromethane (50 mL x 3).
- the combined organic layer was washed with brine and dried over Na 2 S0 4 , filtered and evaporated.
- the residue was purified by silica gel column
- Step d feri-butyl 4-(5-cyano-2-methyl-6-((methyl(l,2,3,4-tetrahydronaphthalen-
- Step b step c
- Step a ethyl 5-bromoimidazo[l,2-a]pyridine-2-carboxylate: The solution of methyl 6- bromopyridin-2-amine (1.7 g, 10 mmol) and ethyl 3-bromo-2-oxopropanoate (2.3 g , 12 mmol) in ethanol (80 mL) was stirred at reflux overnight. The reaction mixture was cooled to room temperature and filtered. The filter cake was dried by oil pump to give the crude desired product (2.8 g) as a white solid. !
- Step a N-methyl-l-(3-methylpyridin-2-yl)ethanamine: To a solution of l-(3- methylpyridin-2- yl)ethanone (500 mg, 3.7 mmol) in THF (10 mL) was added methylamine solution (30 wt percent in absolute ethanol, 14.8 mL) and Ti(OEt) 4 (1.7 g, 7.4 mmol). The reaction mixture was stirred for lOmin at room temperature, before NaB3 ⁇ 4 (563 mg, 14.8 mmol) was added, this reaction mixture was stirred for 2h at room temperature.
- Step b (5)- l-(4-methoxyphenyl)-N-((5)-l-(pyridin-2-yl)ethyl)ethanamine and (5)-l-(4- methoxyphenyl)-N-((R)-l-(pyridin-2-yl)ethyl)ethanamine:
- the solution of l-(pyridin- 2-yl)ethanone (605 mg, 5 mmol) in dichloromethane (30 mL) was added NaBH(OAc)3 (2.12 mg, 10 mmol) and (S)- l-(4-methoxyphenyl)ethanamine (755 mg, 5 mmol) at 0 °C.
- Step c. (5)- l-(4-methoxyphenyl)-N-methyl-N-((5)- l-(pyridin-2- yl)ethyl)ethanamine: The solution of (5)- l-(4-methoxyphenyl)-N-((5)- l-(pyridin-2- yl)ethyl)ethanamine (500 mg, 2 mmol) and formaldehyde (37 wt percent in water, 1 mL) in dichloromethane (20 mL) was added NaBH(OAc) 3 (636 mg, 3 mmol). The resulting suspension was stirred at room temperature overnight.
- Step d. (5)-N-methyl-l-(pyridin-2-yl)ethanamine: To a solution of (5)-l-(4- methoxyphenyl)-N- methyl-N-((5)-l-(pyridin-2-yl)ethyl)ethanamine (400 mg, 1.48 mmol) in dichloromethane (10 mL) was added TFA (5 mL). The mixture was stirred at room temperature overnight. The reaction mixture was concentrated and 1M HCl aqueous (15 mL) was added. The water phase was wash with ethyl acetate (10 mL x 3).
- Step a 8-chloro-5,6,7,8-tetrahydroquinoline: A mixture of 5,6,7,8- tetrahydroquinoline (10 g, 60 mmol) in DCM (200 mL) was added TCCA (21 g, 90 mmol) and stirred at reflux overnight. The reaction mixture was filtered and the filtrate was solution was added saturated NaHC0 3 aqueous solution (50 mL). The organic layer was dried over Na2S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
- Step b N-ethyl-5,6,7,8-tetrahydroquinolin-8-amine: The solution of 8-chloro- 5,6,7,8- tetrahydroquinoline (500 mg, 3 mmol) in ethylamine/ethanol (10 mL) in a sealed tube was stirred at reflux overnight. Then the reaction solution was concentrated and added saturated NaHC0 3 aqueous solution (5 mL) and extracted with dichloromethane (10 mL x 3).
- Step a 5'H-spiro[cyclopropane-l,7'-quinolin]-8'(6'H)-one: To a solution of NaH (60 wt percent moistened with oil, 420 mg, 10.5 mmol) in DMF (50 mL) was added dropwise 6,7-dihydroquinolin-8(5H)-one (441 mg, 3.0 mmol) and 1,2-dibromoethane (1.95g, 10.5 mmol) in DMF (5 mL) in sequence at 0°C under N 2 atmosphere. The reaction was stirred at 0°C for lh.
- Step a.7',8'-dihydro-5'H-spiro[cyclopropane-l,6'-quinoline] To a solution of spiro[2.5]octan-6-one (667 mg, 6 mmol) in ethanol (25 mL) was added prop-2-yn-l-amine (1.3 g, 24 mmol) and NaAuCl 4 (60 mg, 0.15 mmol) in sequence. The reaction was stirred at 85 °C for 1 day. The reaction mixture was concentrated, diluted with ethyl acetate (30 mL) and washed with saturated NaHCC>3 aqueous solution (15 mL) and saturated brine solution (15 mL).
- Step a 3-(4-methoxybenzylamino)picolinonitrile: The solution of 3- fluoropicolinonitrile (10 g, 82 mmol), (4-methoxyphenyl)methanamine (16.8 g, 123 mmol) and CS2CO 3 (40 g, 123 mmol) in DMF (50 mL) was stirred at 70°C overnight. The reaction mixture was concentrated, diluted with ethyl acetate (50 mL) and washed with saturated brine solution (20 mL x 3). The organic layer was dried over Na 2 S0 4 , filtered and evaporated.
- Step b l-(3-(4-methoxybenzylamino)pyridin-2-yl)ethanone: To a solution of 3-
- Step c. N-(2-acetylpyridin-3-yl)acetamide The solution of l-(3-(4- methoxybenzylamino)pyridin- 2-yl)ethanone (1.5 g, 5.8 mmol) in TFA (5 mL) was stirred at room temperature overnight. The reaction mixture was concentrated and added saturated NaHCC> 3 aqueous solution to adjust pH to 8, and extracted with dichloromethane (20 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was dissolved in acetate acid (10 mL), and added AC 2 O (20 mL), stirred at room temperature overnight.
- Step d N-(2-acetylpyridin-3-yl)methanesulfonamide: The solution of l-(3-(4- methoxybenzylamino)pyridin-2-yl)ethanone (1.3 g, 5.1 mmol) in TFA (7 mL) was stirred at room temperature overnight. The reaction mixture was concentrated and added saturated NaHCC>3 to adjust pH to 8, and extracted with dichloromethane (20 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated.
- Step a 4-oxo-4-(pyridin-2-yl)butanal: To a solution of Mg powder (1.06 g, 44 mmol) and I2 (20 mg, 0.08 mmol) in THF (15 mL) was added drop wise the solution of 2-(2- bromoethyl)-l,3-dioxolane (7.16 g, 40 mmol) in THF (15 mL). The reaction mixture was stirred at room temperature for 1.5h. Then this mixture was cooled to 0°C and added drop wise to a THF (10 mL) containing picolinonitrile (2.08 g, 20 mmol) at 0°C. The reaction mixture was stirred at this temperature for 1.5h.
- Step b 2-((5)-l-((R)-l-(4-methoxyphenyl)ethyl)pyrrolidin-2-yl)pyridine: The solution of 4-oxo-4-(pyridin-2-yl)butanal (490 mg, 3 mmol) in dichloromethane (20 mL) was added NaBH(OAc) 3 (1.9 g, 9 mmol) and AcOH (20 mg, 0.33 mmol) at -70°C. The resulting suspension was stirred at the same temperature for 30 min. The reaction was warmed to 0°C and added (R)- l-(4- methoxyphenyl)ethanamine (500 mg, 3.3 mmol).
- Step c. (5)-2-(pyrrolidin-2-yl)pyridine The solution of 2-((5)- l-((R)-l-(4- methoxyphenyl)ethyl)pyrrolidin-2-yl)pyridine (400 mg, 1.48 mmol) in TFA (5 mL) was stirred at 50°C for 12h. The reaction mixture was concentrated and 1M HC1 aqueous (15 mL) was added. This solution was wash with dichloromethane (5 mL x 3). Then saturated NaHC0 3 solution was added to adjust pH to 9, and extracted with dichloromethane (10 mL x 5). The combined organic layer was dried over Na2S0 4 , filtered and evaporated to give the desired product (110 mg, 50%) as a colorless oil.
- Step d 2-((R)-l-((5)-l-(4-methoxyphenyl)ethyl)pyrrolidin-2-yl)pyridine: The solution of 4-oxo-4-(pyridin-2-yl)butanal (326 mg, 2 mmol) in dichloromethane (15 mL) was added NaBH(OAc) 3 (1.27 g, 6 mmol) and HOAc (20 mg, 0.33 mmol) at -70°C. The resulting suspension was stirred at the same temperature for 30 min. The reaction was warmed to 0°C and added (5)-l-(4- methoxyphenyl)ethanamine (332 mg, 2.2 mmol).
- Step e. (R)-2-(pyrrolidin-2-yl)pyridine The solution of 2-((R)-l-((5)-l-(4- methoxyphenyl)ethyl)pyrrolidin-2-yl)pyridine (400 mg, 1.48 mmol) in TFA (5 mL) was stirred at 50°C for 12h. The reaction mixture was concentrated and 1M HC1 aqueous (15 mL) was added. This solution was wash with dichloromethane (5 mL x 3). Then saturated NaHCC>3 solution was added to adjust pH to 9, and extracted with dichloromethane (10 mL x 5). The combined organic layer was dried over Na2S0 4 , filtered and evaporated to give the desired product (100 mg, 45%) as a colorless oil.
- Step a N-(diphenylmethylene)-l-(pyridin-2-yl)methanamine: To the solution of pyridin-2- ylmethanamine (3.97g, 37 mmol) and benzophenone (6.69 g, 37 mmol) in toluene (50 mL) was added p-TsOH (10 mg, 0.058 mmol). The mixture was stirred at reflux overnight. The reaction solution was cooled to room temperature and washed with saturated NaHCC>3 solution (30 mL x 2). The organic layer was dried over Na2S0 4 , filtered and evaporated to give the crude desired product (10 g) as a yellow oil.
- Step b ethyl 4-(diphenylmethyleneamino)-3-methyl-4-(pyridin-2-yl)butanoate:
- the solution of crude N-(diphenylmethylene)-l-(pyridin-2-yl)methanamine (1.5 g), NaOH solution (50 wt percent in water, 110 mg, 2.75 mmol) and BnEtsNCl (60 mg, 0.3 mmol) in acetonitrile (50 mL) was stirred at room temperature for 30 min. Then (£ " )-ethyl but-2-enoate (630 mg, 5.5 mmol) was added. The mixture was stirred at room temperature overnight.
- Step c. 4-methyl-5-(pyridin-2-yl)pyrrolidin-2-one The solution of crude ethyl 4- (diphenylmethyleneamino)-3-methyl-4-(pyridin-2-yl)butanoate (1.3 g) in acetonitrile (15 mL) was added drop wise concentrated HC1 aqueous (3 mL). The mixture was stirred at room temperature for 2h. The reaction solution was washed with dichloromethane (10 mL x 2). The water phase was diluted with acetonitrile (15 mL) and added dropwise ammonia water (5 mL). The mixture was stirred at room temperature for 5h. Then the reaction solution was extracted with dichloromethane (10 mL x 3). The combined organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
- Step d. 2-(3-methylpyrrolidin-2-yl)pyridine The solution of 4-methyl-5-(pyridin- 2-yl)pyrrolidin- 2-one (200 mg, 1.1 mmol) in THF (5 mL) was added LiAlH 4 (174 mg, 4.5 mmol) in portions. The mixture was stirred at reflux overnight. Water (1 mL), NaOH solution (10 wt percent in water, 1 mL) and Water (1 mL) were added in sequence. The mixture was filtered and the filtrate was evaporated to give the desired product (89 mg, 50%) as a yellow oil.
- Step a (£ ' )-2-(pyridin-2-ylmethyleneamino)acetonitrile: The solution of 2- aminoacetonitrile hydrochloride (5.09 g, 55 mmol) and TEA (9.09 g, 90 mmol) in ethanol (250 mL) was added stirred at room temperature for 30 min. Then picolinaldehyde (5.36 g, 50 mmol) was added. The mixture was stirred at room temperature overnight. The reaction solution was concentrated and dissolved in Et20 (200 mL). The mixture was filtered and the filtrate was evaporated to give the crude desired product (4.8 g) as a yellow oil.
- Step c. ds-ethyl 2-(pyridin-2-yl)pyrrolidine-3-carboxylate: To the solution of crude ds-ethyl 5-cyano-2-(pyridin-2-yl)pyrrolidine-3-carboxylate (245 mg, 1 mmol) in THF (5 mL) was added 1M BH 3 /THF solution (2 mL, 2 mmol), and stirred for 20 min. Then cooled to 0°C, NaBH 4 (76 mg, 2 mmol) was added. The mixture was stirred at the same temperature for 3h before room temperature overnight.
- Step a 6-methyl-8-nitroquinoline:
- the pure glycerol (5.0 g, 54 mmol) was heated to 150°C for 30 min. Then it was cooled to 110°C, and added 4-methyl-2-nitroaniline (3.0 g, 20 mmol) and Nal (60 mg, 0.40 mmol). The mixture was heated to 150°C again, and added concentrated sulfuric acid (4.51 g, 46 mmol). The resulting suspension was stirred at this temperature for lh. The reaction mixture was cooled to room temperature and added water (20 mL). This water phase was extracted with dichlorome thane (20 mL x 4). The combined organic layer was evaporated.
- Step b 6-methylquinolin-8-amine: To the solution of 6-methyl-8-nitroquinoline (350 mg, 1.86 mmol) in methanol (30 mL) was added Pd/C (10 wt percent, 0.2 g), and stirred at room temperature under N2 atmosphere overnight. The mixture was filtered and the filtrate was evaporated to give the crude desired product (250 mg, 85%) as a yellow oil.
- H NMR 400 MHz, CDCI 3 ) ⁇ 8.69 (s, IH), 7.98 (s, IH), 7.33 (s, IH), 6.94 (s, IH), 6.79 (s, IH), 4.90 (s, 2H), 2.43 (s, 3H).
- Step a N,6-dimethylquinolin-8-amine hydroiodide: To the solution of 6- methylquinolin-8-amine (250 mg, 1.58 mmol) in ethanol (10 mL) in a sealed tube was added CH 3 I (337 mg, 2.37 mmol), and stirred at reflux overnight. The reaction mixture was cooled to room temperature and filtered. The filter cake was washed with diethyl ether (10 mL) and the filer cake obtained was dried by oil pump to give the crude desired product hydroiodide (200 mg, 42%) as a red solid.
- Step a 5,6,8-trifluoroquinoline: To the solution of concentrated sulfuric acid (18 mL) diluted with water (6 mL), was added 2,4,5-trifluoroaniline (3.68 g, 25 mmol), glycerol (4.60 g, 50 mmol) and sodium 3-nitrobenzenesulfonate (6.75 g, 30 mmol) in sequence. The resulting suspension was stirred at 140°C overnight. The reaction mixture was cooled to room temperature and added saturated NaHCC>3 aqueous solution to adjust pH to 7, extracted with dichloromethane (200 mL x 2). The combined organic layer was evaporated.
- step b 5,6-difluoro-N-methylquinolin-8-amine: To the solution of 5,6,8- trifluoroquinoline (436 mg, 2.38 mmol) and K 2 CO 3 (657 mg, 4.76 mmol) in DMSO (3 mL) in a sealed tube, was added MeN3 ⁇ 4 solution (30 wt percent in ethanol, 3 mL). The resulting suspension was stirred at 120°C for 2 days. The reaction mixture was cooled to room
- Step a l,7-naphthyridin-8-amine: To the solution of concentrated sulfuric acid (15 mL) diluted with water (15 mL), was added pyridine-2, 3 -diamine (1.09 g, 10 mmol), glycerol (4.1g, 33.6 mmol) and sodium 3-nitrobenzenesulfonate (4.5 g, 20.1 mmol) in sequence. The resulting suspension was stirred at 125°C overnight. The reaction mixture was cooled to room temperature and added saturated NaOH aqueous solution to adjust pH to 8, extracted with dichloromethane (100 mL x 2). The combined organic layer was evaporated.
- step b 8-chloro-l,7-naphthyridine: To the solution of l,7-naphthyridin-8-amine (290 mg, 2.0 mmol) in concentrated HCl aqueous solution (5 mL), was added NaN0 2 (1.38 g, 20 mmol) and CuCl (238 mg, 33.6mmol) in sequence. The resulting suspension was stirred at room temperature for 3h. The reaction mixture was added saturated NaHC0 3 aqueous solution to adjust pH to 8, extracted with ethyl acetate (100 mL x 3). The combined organic layer was evaporated.
- Step a 1,6-naphthyridine: To the solution of concentrated sulfuric acid (30 mL) diluted with water (20 mL), was added pyridin-4-amine (3.76 g, 40.0 mmol), glycerol (12.52 g, 136 mmol) and sodium 3-nitrobenzenesulfonate (19.8 g, 88.0 mmol) in sequence. The resulting suspension was stirred at 130°C overnight. The reaction mixture was cooled to room
- step b 8-bromo-l,6-naphthyridine: To the solution of 1,6-naphthyridine (830 mg, 6.38 mmol) in HOAc (5 mL), was added dropwise dibromine (612 mg, 3.83 mmol). The resulting suspension was stirred at 80°C overnight. The reaction mixture was cooled to room temperature and added saturated NaHCC>3 aqueous solution to adjust pH to 8, extracted with dichloromethane (100 mL x 3). The combined organic layer was evaporated.
- step b 4-chloro-l,5-naphthyridine: The solution of 1,5-naphthyridine 1-oxide (3.0 g, 20.5 mmol) in POCI 3 (30 mL), was stirred at 100°C for 6h. The reaction mixture was concentrated and diluted with dichloromethane (100 mL). This solution was added saturated NaHCC>3 aqueous solution to adjust pH to 8. Filtered and the filtrate was partitioned. The water phase was extracted with ethyl acetate (100 mL). The combined organic layer was evaporated.
- Step a N-(2-(pyridin-2-yl)propan-2-yl)formamide: To the solution of 2-(pyridin- 2-yl)propan-2-amine (350 mg, 2.6 mmol) in toluene(10 mL), was added formic acid (237 mg, 5.2 mmol). The resulting suspension was stirred at reflux for 6h. The reaction mixture was cooled to room temperature and added saturated NaHCC>3 aqueous solution (50 mL), the water phase was extracted with dichloromethane (50 mL). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography
- Step b N-methyl-2-(pyridin-2-yl)propan-2-amine: To the solution of N-(2- (pyridin-2-yl)propan-2-yl)formamide (300 mg, 1.8 mmol) in THF (10 mL), was added NaH (60 wt percent moistened with oil, 222 mg, 5.4 mmol). The resulting suspension was stirred at room temperature for 15 min. Then CH 3 I (390 mg, 2.7 mmol) was added, the reaction mixture was stirred at reflux for 2h. The reaction mixture was cooled to room temperature and added the solution of NaOH (252 mg, 6.12 mmol) in methanol (5 mL) and water (1 mL). The reaction mixture was stirred at reflux overnight. The reaction mixture was cooled to room temperature and extracted with dichloromethane (100 mL x 3). The combined organic layer was evaporated. The residue was purified by silica gel column chromatography
- step a step b
- Method AA-Step a N-((6-chloropyrimidin-4-yl)methyl)-N-methyl-5, 6,7,8- tetrahydroquinolin-8- amine: A mixture of N-methyl-5,6,7,8-tetrahydroquinolin-8-amine (160 mg, 1 mmol, see reference WO2006026703), 4-chloro-6-(chloromethyl)pyrimidine (170 mg, 1.05 mmol), KI (16 mg, 0.1 mmol) and DIPEA (320 mg, 2.5 mmol) in CH 3 CN (10 mL) was stirred at room temperature overnight.
- Method AA-Step b N-methyl-N-((6-(4-methylpiperazin- l-yl)pyrimidin-4- yl)methyl)-5,6,7,8- tetrahydroquinolin-8-amine: A mixture of N-((6-chloropyrimidin-4- yl)methyl)-N-methyl-5,6,7,8- tetrahydroquinolin-8-amine (100 mg, 0.35 mmol), TEA (350 mg, 3.5 mmol) and N-methylpiperazine (40 mg, 0.38 mmol) in ethanol (4 mL) was stirred at reflux overnight.
- Method AB-Step a tert-butyl-4-(6-((methyl(5,6,7,8-tetrahydroquinolin-8- yl)amino)methyl)pyrimidin-4-yl)piperazine-l-carboxylate: A mixture of N-((6-chloropyrimidin- 4- yl)methyl)-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine (200 mg, 0.7 mmol), TEA (700 mg, 7 mmol) and tert-butyl piperazine-l-carboxylate (140 mg, 0.77 mmol) in ethanol (10 mL) was stirred at reflux overnight.
- reaction mixture was added saturated NaHCC>3 aqueous solution (50 mL) and extracted with dichloromethane (50 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
- Method AB-Step b N-methyl-N-((6-(piperazin- l-yl)pyrimidin-4-yl)methyl)- 5,6,7,8- tetrahydroquinolin-8-amine: To a solution of tert-butyl-4-(6-((methyl(5,6,7,8- tetrahydroquinolin-8- yl)amino)methyl)pyrimidin-4-yl)piperazine-l-carboxylate (270 mg, 0.6 mmol) in dichloromethane (5 mL) was added dropwise 3M HC1/ ethyl acetate (5 mL). The mixture was stirred at room temperature for 12 h.
- Method AC-Step a N-methyl-N-((2-methyl-6-(4-methylpiperazin- 1 -yl)pyrimidin- 4-yl)methyl)- 5,6,7,8-tetrahydroquinolin-8-amine: A mixture of N-methyl-5, 6,7,8- tetrahydroquinolin-8-amine (37 mg, 0.23 mmol, see reference WO2006026703), 2-methyl-6-(4- methylpiperazin-l-yl)pyrimidine-4- carbaldehyde (46 mg, 0.21 mmol) and AcOH (13 mg, 0.21 mmol) in 1,2-dichloroethane (5 mL) was stirred for 10 min. NaBH(OAc)3 (66 mg, 0.3 mmol) was then added to the reaction solution. The resulting suspension was stirred at room
- Method AD-Step a (5)-N-methyl-N-((2-methyl-6-((R)-2-methylpiperazin- l- yl)pyrimidin-4- yl)methyl)-5,6,7,8-tetrahydroquinolin-8-amine: To a solution of (R)-tert-butyl 3- methyl-4-(2-methyl-6- ((methyl((5)-5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)pyrimidin-4- yl)piperazine-l-carboxylate (50 mg, 0.11 mmol) in ethyl acetate (2 mL) was added 3M HQ/ ethyl acetate (3 mL) and stirred at room temperature overnight.
- reaction mixture was added saturated NaHCC>3 aqueous solution (50 mL) and extracted with dichloromethane (30 mL x 3). The combined organic layer was dried over Na2S0 4 , filtered and evaporated to give the desired product (26 mg, 65%) as a colorless oil.
- Method AD-Step b (5)-N-((6-((R)-2,4-dimethylpiperazin-l-yl)-2- methylpyrimidin-4-yl)methyl)- N-methyl-5,6,7,8-tetrahydroquinolin-8-amine: A mixture of (5)- N-methyl-N-((2-methyl-6-((R)-2- methylpiperazin-l-yl)pyrimidin-4-yl)methyl)-5, 6,7,8- tetrahydroquinolin-8-amine (26 mg, 0.07 mmol) and formaldehyde (37 wt percent in water, 30 mg, 0.36 mmol) in 1,2-dichloroethane (4 mL) was added NaBH(OAc)3 (30 mg, 0.14 mmol).
- Method AE-Step a N-((4-chloropyrimidin-2-yl)methyl)-N-methyl-5,6,7,8- tetrahydroquinolin-8- amine: The mixture of 2-(bromomethyl)-4-chloropyrimidine(94 mg, 0.58 mmol), N-methyl-5,6,7,8- tetrahydroquinolin-8-amine (130 mg, 0.6 mmol, see reference WO2006026703), KI (10 mg, 0.06 mmol) and DIPEA (740 mg, 5.8 mmol) in MeCN (10 mL) was stirred at room temperature for 4h.
- Method AE-Step b N-methyl-N-((4-(4-methylpiperazin- l-yl)pyrimidin-2- yl)methyl)-5,6,7,8- tetrahydroquinolin-8-amine: The mixture of N-((4-chloropyrimidin-2- yl)methyl)-N-methyl-5, 6,7,8- tetrahydroquinolin-8-amine (50 mg, 0.17 mmol), DIPEA (244 mg, 1.7 mmol) and 1-methylpiperazine (87 mg, 0.85 mmol) in NMP (2 mL) was stirred at 200 °C under microwave for 2 h.
- Method AF-Step a N-((6-bromopyridin-2-yl)methyl)-N-methyl-5,6,7,8- tetrahydroquinolin-8- amine: The mixture of 6-bromopicolinaldehyde (162 mg, 0.68 mmol), N- methyl-5,6,7,8- tetrahydroquinolin-8-amine (100 mg, 0.62 mmol, see reference
- Method AF-Step b N-methyl-N-((6-(4-methylpiperazin- l-yl)pyridin-2- yl)methyl)-5,6,7,8- tetrahydroquinolin-8-amine: The mixture of N-((6-bromopyridin-2- yl)methyl)-N-methyl-5,6,7,8- tetrahydroquinolin-8-amine (50 mg, 0.15 mmol), DIPEA (193 mg, 1.5 mmol) and 1-methylpiperazine (73 mg, 0.75 mmol) in NMP (2 mL) was stirred at 120 °C overnight.
- Method AG-Step a N-methyl-N-(pyrimidin-4-ylmethyl)-5,6,7,8- tetrahydroquinolin-8-amine: A mixture of N-((6-chloropyrimidin-4-yl)methyl)-N-methyl- 5,6,7,8-tetrahydroquinolin-8-amine (70 mg, 0.24 mmol) and Pd/C (5 %, 15 mg) in 5 mL of methanol was stirred at 50 °C under 3 ⁇ 4 (1 atm) overnight. The reaction solution was filtered and the filtrate was evaporated.
- Method AH-Step a (4,6-dichloro-2-methylpyrimidin-5-yl)methanol: To POCl 3 (60.6 g, 396.5 mmol) was added dropwise DMF (9.8 g, 134.8 mmol) at 0°C. The resulting suspension was stirred at the same temperature for lh. Then 2-methylpyrimidine-4,6-diol (10 g, 79.3 mmol) was added in portions and stirred at room temperature for lh, after that, stirred at 105 °C overnight. The reaction solution was concentrated and diluted with cold ethyl acetate (lOOmL).
- Method AH-Step b 5-((feri-butyldimethylsilyloxy)methyl)-4,6-dichloro-2- methylpyrimidine: To the solution of (4,6-dichloro-2-methylpyrimidin-5-yl)methanol (2 g, 10.3 mmol) and imidazole (770 mg, 11.3 mmol) in dichloromethane (20mL) was added TBSC1 (1.7 g, 11.3 mmol) in portions. The resulting suspension was stirred at room temperature overnight. Water (20 mL) was added, and extracted with dichloromethane (20 mL). The combined organic layer was dried over Na 2 S0 4 , filtered and evaporated.
- Method AH-Step e (5)-(2-methyl-4-((methyl(l-(pyridin-2- yl)ethyl)amino)methyl)-6-(4- methylpiperazin-l-yl)pyrimidin-5-yl)methanol: The mixture of (5)-(4-chloro-2-methyl-6-((methyl(l- (pyridin-2-yl)ethyl)amino)methyl)pyrimidin-5- yl)methanol (50 mg, 0.16 mmol), TEA (80 mg, 0.8 mmol) and l-methylpiperazine (48 mg, 0.48 mmol) in ethanol (5 niL) was stirred at reflux overnight. The reaction solution was evaporated. The residue was purified by silica gel column chromatography
- reaction mixture was added saturated NaHC0 3 aqueous solution (100 mL) and extracted with dichloromethane (100 mL). The organic layer was dried over Na 2 S0 4 , filtered and evaporated to give the desired product (35 mg, 86%) as a white solid.
- Method AJ-Step a (8-(methyl((2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin-4- yl)methyl)amino)quinolin-6-yl)methanol: The solution of methyl 8-(methyl((2-methyl-6-(4- methylpiperazin- 1 -yl)pyrimidin-4-yl)methyl)amino)quinoline-6-carboxylate( 105 mg, 0.25 mmol) in THF (3 mL) was added L1AIH 4 (19 mg, 0.5 mmol) at 0°C, and stirred at room temperature for 20 min. Water and NaOH aqueous solution (15wt percent in water) was added to quench the reaction.
- Method AK-Step a (5)-5-bromo-2-((2-(3-methylpyridin-2-yl)pyrrolidin-l- yl)methyl)imidazo[l,2- jpyridine: The mixture of 5-bromo-2-(bromomethyl)imidazo[l,2- ]pyridine(48 mg, 0.17mmol), (5)-3-methyl-2-(pyrrolidin-2-yl)pyridine (30 mg, 0.12 mmol), KI (3 mg, 0.017 mmol) and K 2 C0 3 (46 mg, 0.34 mmol) in MeCN (15 mL) was stirred at room temperature overnight. The reaction mixture was filtered and the filtrate was evaporated.
- Method AL-Step a 7,7-difluoro-6,7-dihydroquinolin-8(5H)-one: To a solution of NaH (60 wt percent moistened with oil, 511 mg, 12.8 mmol) in THF (20 mL) was added dropwise the THF solution (5 mL) containing 6,7-dihydroquinolin-8(5H)-one (588 mg, 4 mmol) at 0°C. The reaction was stirred at 0°C for 10 min followed by adding selectfluro (3.0 g, 8.4 mmol) in portions. The reaction mixture was stirred at room temperature for lh. Water (20 mL) was added to quench the reaction.
- Method AL-Step b.7,7-difluoro-N-methyl-5,6,7,8-tetrahydroquinolin-8-amine The solution of 7,7-difluoro-6,7-dihydroquinolin-8(5H)-one (18.3 mg, 0.1 mmol), MeNH 2 solution (30 wt percent in ethanol, 1 mL) and HO Ac (5 mg, 0.083 mmol) in 1,2-dichloroethane (2 mL) was added NaBHsCN (13 mg, 0.2 mmol). The resulting suspension was stirred at room temperature overnight. The reaction mixture was filtered and the filtrate was evaporated.
- Method AM-Step a N-methyl-N-((2-methyl-6-(4-methylpiperazin- 1 - yl)pyrimidin-4- yl)methyl)quinolin-8-amine: A mixture of N-((2-methyl-6-(4-methylpiperazin-l- yl)pyrimidin-4- yl)methyl)quinolin-8-amine (75 mg, 0.26 mmol) and formaldehyde (37 wt percent in water, 42 mg, 0.52 mmol) in methanol (3 mL) was added NaB3 ⁇ 4CN (25 mg, 0.4 mmol). The resulting suspension was stirred at room temperature overnight. Water (10 mL) was added to quench the reaction.
- Method AN-step a N-methyl-N-((2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin- 4-yl)methyl)- l,7-naphthyridin-8-amine: To the solution of 8-chloro-l,7-naphthyridine (56 mg, 0.34 mmol) and N- methyl- l-(2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin-4-yl)methanamine (80 mg, 0.34 mmol) in DMSO (3 mL), was added K 2 C0 3 (140 mg, 1.02 mmol). The resulting suspension was stirred at 110°C overnight. The reaction mixture was concentrated.
- Method AO-step a N-methyl-N-((2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin-
- Method AP-Step a 4-(((2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin-4- yl)methyl)(quinolin-8- yl)amino)butanoic acid: The solution of feri-butyl 4-(((2-methyl-6-(4- methylpiperazin-l-yl)pyrimidin- 4-yl)methyl)(quinolin-8-yl)amino)butanoate (55 mg, 0.112 mmol) in concentrated HCl aqueous solution (6 mL) was stirred at 50°C overnight. The reaction mixture was evaporated to give the desired product hydrochloride (535 mg, 96%) as a yellow oil.
- Method AP-Step b 4-(((2-methyl-6-(4-methylpiperazin-l-yl)pyrimidin-4- yl)methyl)(quinolin-8- yl)amino)butanamide: The mixture of 4-(((2-methyl-6-(4- methylpiperazin-l-yl)pyrimidin-4- yl)methyl)(quinolin-8-yl)amino)butanoic acid (50 mg, 0.098 mmol), NH 4 C1 (27 mg, 0.51 mmol), HATU (47 mg, 0.122 mmol) and DIPEA (131 mg, 1.02 mmol) in DMF (3 mL) was stirred at 50°C overnight. The reaction mixture was concentrated. The residue was purified by silica gel column chromatography
- the reaction mixture was stirred at room temperature for lh.
- the 2M NaOH aqueous solution was added to adjust pH to 11 and stirred for lh.
- the mixture was partitioned and the water phase was added 6MHC1 aqueous solution to adjust pH to 5.
- the saturated NaHCC>3 aqueous solution was added to adjust pH to 8 and extracted with ethyl acetate (30 mL x 3).
- the combined organic layer was evaporated.
- Method AA-Step b (5)-N-methyl-N-((2-methyl-6-(4-methylpiperazin- 1 - yl)pyrimidin-4-yl)methyl)- l-(pyridin-2-yl)ethan-l-amine: A mixture of (5)-N-((6-chloro-2- methylpyrimidin-4-yl)methyl)-N-methyl-l-(pyridin-2-yl)ethan-l -amine (90 mg, 0.33 mmol), TEA (333 mg, 3.3mmol) and N-methylpiperazine (163 mg, 1.6 mmol) in ethanol (10 mL) was stirred at reflux overnight. The reaction mixture was concentrated.
- Method AK-Step a (5)-N-((5-bromoimidazo[l,2- ]pyridin-2-yl)methyl)-N- methyl- l-(pyridin-2-yl)ethan- l-amine: The mixture of 5-bromo-2-(bromomethyl)imidazo[l,2- jpyridine (127 mg, 0.4 mmol), (5)-N-methyl-l-(pyridin-2-yl)ethanamine (55 mg , 0.4 mmol), KI (7 mg, 0.04 mmol) and DIPEA (130 mg, 1 mmol) in MeCN (10 mL) was stirred at room temperature overnight. The reaction mixture was evaporated.
- Method AK-Step b (5)-N-methyl-N-((5 -(4-methylpiperazin- l-yl)imidazo[l, 2- ]pyridin-2-yl)methyl)- l-(pyridin-2-yl)ethan-l -amine: The mixture of (5)-N-((5- bromoimidazo[ 1 ,2- ]pyridin-2-yl)methyl)-N- methyl- 1 -(pyridin-2-yl)ethan- 1-amine (100 mg , 0.29 mmol) in N-methylpiperazine (3 mL) was stirred at 190°C under microwave for 2 h. The reaction mixture was concentrated. The residue was purified by silica gel column
- reaction mixture was added saturated NaHCC>3 aqueous solution (10 mL) and extracted with dichloromethane (20 mL). The organic layer was dried over Na2S0 4 , filtered and evaporated. The residue was purified by silica gel column chromatography
- Table 1 shows a selection of the compounds prepared according to the methods discussed above in details and indicated in the third column of the table.
- A5 A AA 2.57 (s, 6H), 2.39 (s, 3H), 2.11 (s, IH), 2.00 (s, IH),
- HPB-ALL cells were maintained in RPMI-1640 (Gibico) supplemented with 10% FBS (Hyclone).
- APC-conjugated anti-human CXCR4 was from Surgie. ECso was first determined for 12G5 binding to CXCR4. Then the compounds for testing were added into 96- well plates serially diluted at a ratio of 1:3. Cells were washed once with ice-cold assay buffer (DPBS+2% HI-FBS) and then re-suspended in the same buffer at a final concentration of 1 x 10 6 /mL.
- DPBS+2% HI-FBS ice-cold assay buffer
- Tables 2 summarize results of the CXCR4 competitive binding assay for selected compounds disclosed in the present disclosure.
- Table 3 summarizes results of the CXCR4 competitive binding assay for control compounds.
- FIGs. 1-2 depict the IC 50 curves of compounds A42 and A43. [00408] Table 2. Results of selected compounds of the present invention tested by thel2G5 binding assay
- the FLIPR Tetra calcium mobilization assay was performed by HD Bioscience. Briefly, The Molecular Devices, Fluorescent Imaging Plate Reader (FLIPR) Tetra was used in this assay. Excitation was achieved through unique placement of LED' s within the instrument and emission captured by a CCD camera (EMCCD camera for FI and ICCD camera for luminescence). The homogeneous FLIPR Calcium 4 assay kit from Molecular Devices was used as the fluorescence reagent. Compounds were solubilized in 100% dimethyl sulfoxide (DMSO) to a concentration of 30 mM.
- DMSO dimethyl sulfoxide
- a 10-point, 4-fold, intermediate dilution series was created in 100% DMSO with a top concentration of 4 mM and a bottom concentration of 0.01 ⁇ .
- a near assay ready, direct dilution plate (ddNARP) was prepared from this compound dilution plate by transferring 1 ⁇ ⁇ of each dilution of compound in 100% DMSO to a Greiner#781201 plate.
- each ddNARP plate also contained positive and negative control wells to define the upper and lower limits for the assay signal.
- the final assay concentration range of compound was 10 ⁇ to 0.035 nM in 0.5% DMSO.
- Human CD 4+ T-Cells were isolated from human whole blood and subsequently activated and expanded using a CD3/CD28 expansion kit (Life Technologies). The cells were frozen in ThermoFisher-formulated Recovery Cell Culture Freezing Medium containing 10% Dimethyl sulfoxide (DMSO) and 10% Fetal Bovine Serum (FBS) (ThermoFisher Catalog No. 10100147). When used, cells were resuspended using room temperature IX HBSS/20mM HEPES/0.005% P-104 assay buffer, adjusted the volume of the suspension to achieve a cell concentration of 2.5 x 10 6 cells/mL.2X Calcium 4 dye (20 ⁇ ⁇ ) were added and the mixture were centrifuged briefly ( ⁇ 10s) and stopped when it reached 1000 rpm.
- DMSO Dimethyl sulfoxide
- FBS Fetal Bovine Serum
- the plates were allowed to equilibrate before compounds and CXCL12 were added to the plates.
- the raw data were analyzed using Abase.
- the percent (%) effect at each concentration of compound was calculated by Abase and was based on and relative to the amount of calcium produced in the positive and negative control wells contained within each assay plate.
- the concentrations and % effect values for tested compounds were plotted by Abase and the concentration of compound required for 50% effect (IC 50 ) was determined with a four-parameter logistic dose response equation.
- Table 4 summarizes the results of selected compounds in the calcium mobilization assay.
- FIGs. 3 and 4 summarize the results of Compounds A78 and A83 in the calcium mobilization assay.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710875041 | 2017-09-25 | ||
CN201810265417.9A CN110317191B (en) | 2018-03-28 | 2018-03-28 | Pyridine heterocyclic compound and application thereof as CXCR4 inhibitor |
CN201810710340.1A CN110669036B (en) | 2018-07-02 | 2018-07-02 | Heterocyclic compounds with CXCR4 signal channel inhibition activity and application thereof |
CN201811034891.7A CN109553604B (en) | 2017-09-25 | 2018-09-05 | 4-aminopyrimidine derivatives as CXCR4 inhibitors and uses thereof |
PCT/US2018/052503 WO2019060860A1 (en) | 2017-09-25 | 2018-09-24 | Heteroaryl compounds as cxcr4 inhibitors, composition and method using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3687540A1 true EP3687540A1 (en) | 2020-08-05 |
EP3687540A4 EP3687540A4 (en) | 2021-04-21 |
Family
ID=65809950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18859565.6A Pending EP3687540A4 (en) | 2017-09-25 | 2018-09-24 | Heteroaryl compounds as cxcr4 inhibitors, composition and method using the same |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3687540A4 (en) |
KR (1) | KR20200058443A (en) |
WO (1) | WO2019060860A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL269379B (en) | 2017-02-21 | 2022-06-01 | Univ Emory | Chemokine cxcr4 receptor modulators and uses related thereto |
WO2019183133A1 (en) | 2018-03-19 | 2019-09-26 | Emory University | Pan-Tropic Entry Inhibitors |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
CA3188639A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080045537A1 (en) * | 2004-08-16 | 2008-02-21 | Kristjan Gudmundsson | Chemical Compounds |
JP2008511669A (en) * | 2004-09-02 | 2008-04-17 | スミスクライン ビーチャム コーポレーション | Compound |
EP1838312A4 (en) * | 2004-12-17 | 2010-01-20 | Smithkline Beecham Corp | Chemical compounds |
WO2007027999A2 (en) * | 2005-08-31 | 2007-03-08 | Smithkline Beecham Corporation | Chemical compounds |
US20080051387A1 (en) * | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
KR20110005819A (en) * | 2008-03-28 | 2011-01-19 | 알티리스 쎄라퓨틱스 | Chemokine receptor modulators |
WO2010025416A1 (en) * | 2008-08-29 | 2010-03-04 | Genzyme Corporation | Cxcr4 antagonists for kidney injury |
CN102675305B (en) * | 2011-03-08 | 2014-11-12 | 中国科学院上海药物研究所 | Imidazopyridine compounds, as well as preparation method and application thereof |
CN103570683B (en) * | 2012-07-30 | 2018-04-17 | 中国科学院上海药物研究所 | Polysubstituted aminated compounds and its preparation method and application |
US10709697B2 (en) * | 2015-07-16 | 2020-07-14 | Emory University | Bis-amines, compositions, and uses related to CXCR4 inhibition |
EP3472129A4 (en) * | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
-
2018
- 2018-09-24 WO PCT/US2018/052503 patent/WO2019060860A1/en unknown
- 2018-09-24 EP EP18859565.6A patent/EP3687540A4/en active Pending
- 2018-09-24 KR KR1020207010206A patent/KR20200058443A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2019060860A1 (en) | 2019-03-28 |
EP3687540A4 (en) | 2021-04-21 |
KR20200058443A (en) | 2020-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3687540A1 (en) | Heteroaryl compounds as cxcr4 inhibitors, composition and method using the same | |
AU2016225896C1 (en) | Heterocyclic compounds useful as PDK1 inhibitors | |
KR102030305B1 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
JP2022518860A (en) | Immunomodulators, compositions and their uses | |
KR102345381B1 (en) | Carbazole carboxamide compounds useful as kinase inhibitors | |
EP4304720A1 (en) | Mta-cooperative prmt5 inhibitors | |
WO2005066171A1 (en) | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | |
WO2006118598A1 (en) | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof | |
JP6782766B2 (en) | 5- (N-benzyltetrahydroisoquinoline-6-yl) pyridine-3-ylacetic acid derivative as an inhibitor of human immunodeficiency virus replication | |
KR20170075756A (en) | Carbazole derivatives | |
PT3013814T (en) | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors | |
CN112110938B (en) | Compound as protein kinase inhibitor and preparation method and application thereof | |
EP3860998B1 (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
CN117242056A (en) | Novel compounds useful as STING agonists and uses thereof | |
CN112823159B (en) | Aromatic heterocyclic compounds with kinase inhibitory activity | |
CN109666022B (en) | Triazole derivative and preparation method and application thereof | |
US11964987B2 (en) | Isoidide derivatives and methods of making and using same | |
JP7282786B2 (en) | Heteroaryl compounds, compositions and methods using same as CXCR4 inhibitors | |
CN109553604B (en) | 4-aminopyrimidine derivatives as CXCR4 inhibitors and uses thereof | |
CA3179671A1 (en) | Kinase inhibitors and uses thereof | |
AU2018337138B2 (en) | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | |
CN109956929B (en) | Heterocyclic derivative, preparation method, pharmaceutical composition and application thereof | |
WO2019196918A1 (en) | Five-membered heterocyclo-pyrimidine compound, pharmaceutical composition and use thereof | |
CN110669036A (en) | Heterocyclic compounds with CXCR4 signal channel inhibition activity and application thereof | |
KR102655210B1 (en) | Adenosine A2A receptor antagonists and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200326 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/444 20060101AFI20210208BHEP Ipc: A61P 11/00 20060101ALI20210208BHEP Ipc: A61P 35/00 20060101ALI20210208BHEP Ipc: C07D 401/14 20060101ALI20210208BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210324 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/444 20060101AFI20210318BHEP Ipc: C07D 401/14 20060101ALI20210318BHEP Ipc: A61P 11/00 20060101ALI20210318BHEP Ipc: A61P 35/00 20060101ALI20210318BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220802 |